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1 Introduction 
Bacterial pathogens interact with the mammalian immune system that could 
lead to bacterial clearance or pathology. Mycobacteria are one of the well-
known examples of bacteria that cause disease. 
1.1 Mycobacteria 
The genus Mycobacterium belongs to the family of Mycobacteriaceae. They are 
acid-fast, aerobic, rod shaped, Gram positive bacteria and have a lipid-rich cell 
envelope (Figure 1.1). One of the characteristic of mycobacteria is the cell wall 
which is differing from other Gram positive bacteria. It is thicker than any other 
Gram positive bacteria. The plasma membrane of mycobacteria contains 
phosphatidylinositol mannoside which is glycosylated to lipoarabinomannan 
(LAM) and lipomannan (LM) in some of the species. The cell wall skeleton is 
composed of a peptidoglycan layer linked to polysaccharide side chains 
consisting of arabinogalactan. These chains are substituted with myolic acids. 
The complexity of mycobacterial cell wall results in difficulties for many 
compounds to penetrate to the cell wall thus causing multidrug resistance. 
Another characteristic that can differentiate the genus Mycobacterium from 
other closely related genera such as Nocardia, Rhadococcus and 
Corynebacterium is the molecular predominance of 61 to 71 % of guanine + 
cytosine content in the genome  (Over et al., 2011).  
More than 100 different Mycobacterium species have been described. The 
majority of mycobacteria species are non-pathogenic environmental bacteria. 
However, some of them are clinical important because they are animal and 
human pathogens. The pathogenic mycobacteria usually exhibit slow growth in 
comparison to environmental mycobacteria and have the ability to establish 
residence and to proliferate inside host macrophages. These pathogenic 
bacteria could survive although the cells have antimicrobial properties. The 
firstly described pathogenic mycobacteria were M. tuberculosis and M. leprae 
being the cause of tuberculosis and leprosy in humans (Cosma et al., 2003). 
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Pathogenic mycobacteria can generally be divided into several groups; M. 
tuberculosis complex, M. marinum and M. ulcerans, M. leprae, and M. avium 
complex (MAC). 
 
Figure 1.1 Scanning electron microscope image of MAP 
Scanning electron microscope image of MAP attaching to murine intestinal epithelial cell line 
mICcl2 showed the rod shaped of MAP (Pott et al., 2009).  
 
M. bovis, M. africanum, M. mircroti, M. canettii and M. tuberculosis which are 
the member of Mycobacterium tuberculosis complex can cause tuberculosis in 
humans and animals. Humans are the only natural host for M. tuberculosis. In 
contrast, M. bovis has a broad host range in mammals including humans and 
cattle. Another important mycobacteria species is M. marinum, because it is the 
closest relative of M. tuberculosis complex organism. M. marinum causes a 
tuberculosis-like granulomatous infection and disease in fish and frogs as theirs 
natural hosts. Zebrafish (Dario rario) is a particularly model system that is often 
being used to study this type of tuberculosis.  
 
1.1.1 Mycobacterium avium complex 
The other group of mycobacteria is Mycobacterium avium complex (MAC). MAC 
is an environment related mycobacteria and known as nontuberculous 
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mycobacteria or atypical mycobacteria. These bacteria have been isolated from 
environment including water, soil, dust and plants (Falkinham et al., 2001). MAC 
has been known as an opportunistic respiratory infection in immune 
compromised individuals, particularly in AIDS patients and in elderly individuals. 
MAC may cause progressive parenchymal lung disease and bronchiectasis in 
patients.  
MAC consists of M. avium, M. intracellulare, M. lepraemurium and M. silvaticum. 
M. avium comprises subspecies such as M. avium ssp. avium (MAA), M. avium 
ssp. hominissuis (MAH) and M. avium ssp. paratuberculosis (MAP) (Over et al., 
2011) which infect different host. MAA is the causative agent of tuberculosis in 
birds, but also in patients with AIDS, cervical lymphadenitis in children and 
chronic lung disease in cystic fibrosis patients. Whereas MAH is an 
opportunistic pathogen found in human and swine (Bruijnesteijn van Coppenraet 
et al., 2008). Importantly, MAP is a significant pathogen of livestock causing 
Johne’s disease and has been discussed to be involved in Crohn’s disease 
(Cosma et al., 2003). 
 
1.1.2 Mycobacterium avium ssp paratuberculosis 
Mycobacterium avium ssp. paratuberculosis (MAP) is the only etiological agent 
of chronic inflammatory bowel disease in ruminants, known as Johne’s disease 
(JD)(Harris and Barletta, 2001). MAP also has been implicated in Crohn’s 
disease in humans. MAP is an extremely slow growth bacterium that forms 
colonies after several months or even years (Bull et al., 2003). MAP is clumping 
in the culture (Merkal and Curran, 1974) and depends on iron chelating 
mycobactin (Merkal and McCullough, 1982). By polymerase chain reaction 
(PCR), insertion element (IS) 900 is usually used to distinguish MAP from other 
mycobacteria (Green et al., 1989). However, the waxy materials contained in 
the MAP cell wall renders the cells particularly difficult to disrupt to release DNA 
for PCR (Grant, 2005). Three main groups of MAP strains are distinguished 
based on the molecular characterization. The groups are called sheep or Type I, 
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cattle or Type II and intermediate or type III. Types I and III are being sometimes 
grouped as type I/III due to their close genetic homology (Carta et al., 2013).  
MAP is a host-dependent organism which differentiates it from other members 
of MAC (Olsen et al., 2002). It can survive over a long period of time in the 
environment like in soil and water, but MAP can only replicate inside 
macrophages (Grant, 2005).  Interestingly, some studies found that MAP is 
more resistant to heat treatments than other mycobacteria including M. avium, 
M. chelonae, M. xenopi and M. scrofulaceum (Schulze-Röbbecke and 
Buchholtz, 1992). Strikingly, MAP exhibits a high tenacity and can survive after 
low-temperature holding treatment at 63oC for 30 minutes and high 
temperature-short time (HTST) treatment at 72oC for 15 seconds (Millar et al., 
1996; Sung and Collins, 1998). In addition, another study constructed thermal 
death curves for MAP and concluded that pasteurization process was not 
sufficient to ensure the complete destruction of the organism (Grant et al., 
1996). These studies are important since milk might be involved in the 
transmission of MAP from infected animals to other animals or humans. 
 
1.2 Inflammatory bowel disease 
Inflammatory bowel disease (IBD) in humans consists of Crohn’s disease (CD) 
and ulcerative colitis (UC). Although they share many clinical symptoms, they 
have distinct characteristics. The location of the inflammation in CD occurs 
anywhere along the digestive tract from mouth to the anus. In UC, the colon is 
typically the only site that is affected. However, only CD will be discussed in 
more detail due to its correlation with MAP. Furthermore, Johne’s disease is 
known as an inflammatory bowel disease that affects animals. 
1.2.1 Johne’s disease 
Johne’s disease (JD) or paratuberculosis is a chronic, progressive and 
ultimately fatal disease in the intestines affecting domestic and wild ruminants 
like cattle, sheep, goats and deer. It was firstly described by German scientist 
H.A Johne and L. Frothingham in 1895 (Harris and Barletta, 2001). F. W. Twort 
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was able to culture MAP in the laboratory and transmit the infection thus 
meeting Koch’s postulates in 1912. As described previously, JD is caused by 
MAP and characterized by regional lymphangitis and lymphadenitis and chronic 
granulomatous enterocolitis. In the infected host, large lesions, segmental or 
diffuse are usually seen in the intestines and mesenteric lymph nodes (Olsen et 
al., 2002).  One study described the pathological finding from MAP infected 
goats showed transmural granulomatous enteritis and often was found with 
abundant acid-fast bacilli (Lybeck et al., 2013). These were more evident in the 
proximal jejunum and jejunal lymph nodes (Figure 1.2).The clinical symptoms of 
JD are loss of body weight, diarrhea, decreased in milk production and death in 
the later stage (Clarke, 1997). Dairy industry is affected significantly due to 
productivity loss, infertility and direct cost of diagnosis and control. The infected 
animals show decreased milk production and need to be culled because they 
shed large amounts of MAP in feces and milk which can transmit the bacteria. 
The bacteria most likely transmit via the fecal oral route either through 
contaminated milk, colostrum, feces or surfaces and residence in the upper 
gastrointestinal tract, especially in the mucosa-related lymphoid tissue. Other 
route of transmitting the bacteria is via intrauterine transfer to the unborn fetus. 
After first exposure to MAP, animals like cattle need 2 to 5 years incubation 
phase until the clinical phase starts (Collins, 1997; Grant, 2005). During 
incubation phase or subclinical phase, there is no clinical symptoms can be 
detected.  
The diagnosis of JD is not simple due to lack of reliable diagnostic tools. Culture 
of MAP from feces as a gold standard requires at least 6 week incubation due to 
bacterial slow growth. This is not only due to the long period of incubation, but 
also the sensitivity, especially for fecal culture of subclinical infected animals, 
render the culture method not a reliable method for diagnostics. In addition, 
certain MAP types or form may be more difficult or even impossible to isolate ex 
vivo (Chiodini et al., 1986; Stabel, 1998).  Serological assays have been turned 
out to be unreliable because animals do not develop antibodies during the 
subclinical phase. MAP specific antibodies can only be detected during the 
clinical stages of the disease (Stabel, 1998).   
 
 
Introduction 
10 
 
 
 
Figure 1.2 Microscopical lesion in the jejenum and jejunal lymph node of MAP 
infected goat.  
A.H&E staining of transmural granulomatous enteritis in the proximal jejenum with aggregation 
of lymphocytes in submucosa and serosa (arrow). B. Higher magnification of (A) showing 
infiltration of macrophages and lymphocytes. C. H&E staining of jejunal lymph node with 
granulomatous lesions and necrosis (arrows). D. Ziehl-Neelsen staining within the necrotic 
lesion showed acid-fast bacteria in macrophages. Bars, 1,000 µm (A and C), 500 µm (D), 100 
µm (B) (Lybeck et al., 2013). 
 
To control MAP, vaccinations are available commercially including killed whole-
cell-based vaccines and live-attenuated whole-cell based vaccines. The current 
vaccination was found to slow the rate of occurrence of clinical paratuberculosis. 
However, this measure could not prevent infection, since is no protective 
immunity conferred.  In addition, complications in diagnosing infected animals 
may arise from the use of vaccines due to false-positive serological test results 
(Over et al., 2011). 
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1.2.2 Crohn’s disease 
As described above, Crohn’s disease (CD) is a relapsing inflammatory bowel 
disease (IBD) in humans involving mucosal ulceration and inflammation with 
uncertain etiology. CD can affect any part of the gastrointestinal tract from 
mouth to anus, but manifest itself primarily in the terminal ileum and colon 
(Hermon-Taylor and Bull, 2002). Recently, the prevalence of CD rapidly 
increased in developed countries which seriously impact the quality of life in 
patients (Kappelman et al., 2007; Loftus, 2004). The clinical symptoms of CD 
are chronic inflammation, abdominal pain, loss of body weight, bloody diarrhea 
and malnutrition (Hermon-Taylor and Bull, 2002). Transmural inflammation of 
entire bowel wall in CD leads to atrophy of ileal villi, fibrosis, hypertrophy of 
smooth muscle and an inflammatory response.  
The pathogenic mechanisms of CD are still poorly understood. Genetic 
dispositions (Consortium, 2007; Rioux et al., 2007), autoimmunity (Cerf-
Bensussan and Gaboriau-Routhiau, 2010), an inappropriate immune response 
to the intestinal microbiota (Chassaing and Darfeuille-Michaud, 2011), certain 
pathogenic bacteria (Greenstein, 2003; Selby, 2004) and combinations of such 
factors (Cadwell et al., 2010) have been proposed as the cause of CD.  
Current understanding of the genetics in CD is that the genes associated with 
CD regulate innate immune responses, mucosal barrier function and bacterial 
killing (Sartor, 2006) play an important role in susceptibility of the disease. 
Recently, genome-wide association studies (GWAS) have revealed more than 
100 genetic loci that show significant association with IBD (Franke et al., 2010). 
Genetic variation in intracellular pattern recognition receptor gene CARD15 or 
known as NOD2 and an autophagy gene ATG16L1 are the examples of gene 
associated with CD. Additionally, variation in genes encoding interleukin-23 (IL-
23) receptor subunit, IL12B, STAT3 and NKX2-3 also showed their association 
with CD  (Cho, 2008).   
Loss tolerance and autoinflammatory disorder apparently contributes to the 
progression of CD. Highly activated innate and acquired immune responses 
were detected in CD patients. Effector macrophages as well as neutrophils 
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representing innate immune system and T cells of acquired immune system 
accumulate in the inflamed intestine. They are the producers of proinflammatory 
cytokines which are the characteristics of pathogenesis of CD. The best 
established mechanism is the dysregulation of T effector cells responding to the 
commensal intestinal. A disturbed balance between regulatory T cells (Tregs) 
and T effector cells which results in a disable immune homeostasis leads to 
development of the disease (Maynard and Weaver, 2009). 
Certain pathogenic bacteria were suggested as one of the causing of CD. 
Mycobacterium avium ssp. paratuberculosis (MAP) as the focus in this thesis 
has been postulated involving in pathogenesis of CD, since CD shares clinical 
symptoms and histopathological appearance with an Johne’s disease (Figure 
1.3)  (Greenstein and Collins; Hermon-Taylor and Bull, 2002). However, studies 
to reveal the presence of MAP in the intestine of CD patients have given 
contradictory results (Abubakar et al., 2008; Chiodini et al., 2012). Several 
meta-analyses revealed a positive correlation between intestinal presence of 
MAP and CD (Feller et al., 2007). Difficulties in cultivating MAP from clinical 
isolates might be one explanation for the controversial reports, as many MAP 
strains need months or even years to form colonies on solid media (Bull et al., 
2003). Interestingly, cell wall deficient MAP called spheroplast were found in 
tissue of CD patients that could not be stained with conventional dyes and failed 
to grow in hypertonic media (Chiodini et al., 1986). Alternatively, MAP might be 
situated in anatomical locations like the mesentery that are usually not 
examined by standard techniques, as suggested recently (Pierce, 2009). Hence, 
the question whether MAP plays a causative or disease promoting role in CD is 
still remaining unanswered. 
CD is such a complex disease that makes discussion of the etiology 
controversial. However, understanding the complex interplay between genetic 
and environmental factors might help to understand the etiology of CD. 
Interestingly, one study demonstrated that an interaction between a specific 
virus infection and a mutation in the CD susceptibility gene ATG16L1 can 
induce intestinal pathologies in mice. This study provided an example that a 
virus and host susceptibility gene, in combination with environmental factors 
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such as microbiota, can generate the phenotype that is prone to inflammatory 
disease (Cadwell et al., 2010). 
 
 
Figure 1.3 Mucosal cobblestoning in Johne’s and Crohn’s disease. 
Creeping mesenteric fat as the characteristic of Crohn’s disease, can be seen on serosal 
surface in Johne’s disease. A. bovine Johne’s disease. B. Crohn’s disease (Greenstein and 
Collins). 
 
Treatments for CD depend in the specific symptoms and individual severity. 
Aminosalicylates (sulfasalazine and mesalamine), antibiotics (rifampin, 
ciprofloxacin and metronidazole), conticosteroids (budesonide and prednisone) 
and immunomodulators (azathioprine, 6-mercaptopurine and methotrexate) are 
used for the treatment of mild to moderate disease activity. This is the condition 
that the patients are still able to tolerate oral alimentation. For severe symptoms, 
intravenous corticosteroids or anti TNF (infliximab) were used (Baumgart and 
Sandborn, 2007; Over et al., 2011).  Nevertheless, development of new drugs 
with better efficacies and less adverse effect is still needed. 
Animal models are important to provide fundamental insight into the 
pathogenesis of IBD in general, CD in particular. This could assist the 
development of new and better therapies against the disease. Mouse represent 
the most commonly used animals for such models due to the availability of 
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distinct inbred strains as well as the access to genetic deficient and transgenic 
animals that allow to investigate host mechanisms in detail. Many mouse 
models have been established to study the disease. Interleukin (IL)-10 and 
transforming growth factor (TGF)-β deficient mice were often used because 
those mice develop colitis which is the clinical symptoms of CD (Li and Flavell, 
2008). Both cytokines have been known as a regulatory cytokines which down 
regulate immune activation and are important in immune tolerance.  Transfer of 
a subpopulation of T cells (CD4+CD45RBhi) to lymphopenic mice which leads to 
colitis which represents an important model to study specific T cells involvement 
in dysregulation (Powrie et al., 1994). Interestingly, another study that utilized 
previously described mouse model combined with co-transfer of CD4+CD25+ T 
cells could suppress colitis development (Sakaguchi et al., 1995). This study is 
important in proving the anti-inflammatory role of FoxP3+ regulatory T cells 
which is a therapeutic option for CD treatment.   
The dextran sulfate sodium (DSS) mouse model was also frequently used to 
study inflammatory bowel disease.  Administration of DSS in drinking water 
exerts a direct cytotoxic effect on enterocytes and the protective mucus layers 
resulting in barrier damage and translocation of commensal bacteria associated 
with an inflammatory response (Johansson et al., 2013; Saleh and Elson, 2011). 
In the DSS model, the innate immunity such as TLRs and inflammasomes are 
important for tissue repair and host protection from translocation of commensal 
bacteria (Kirkland et al., 2012; Saleh and Elson, 2011). Even though the 
adaptive immunity does not play an essential role in this model, both T helper 
(Th)1 and Th2 cells have been shown the influence the disease at the later 
phases.  
 
1.3 Immunology of MAP infection 
It is important to study immune response in MAP infection to cure the disease. 
However, detail studies about immune response of the host against 
mycobacteria have been carried out mostly in M. tuberculosis infection. 
Nevertheless, the course MAP infection is beginning to be understood. Upon 
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oral exposure of the host to MAP, the pathogen enters the intestinal mucosa via 
M cells in the epithelium that lines the dome areas of Peyer’s patches or via 
enterocytes (Figure 1.4) (Bermudez et al., 2010). MAP is recognized by resident 
macrophages or dendritic cells then phagocytosed and persists within 
subepithelial macrophages (Momotani et al., 1988). Other immune cells 
including polymorphonuclear cells (PMNs), DC and natural killer cells are 
recruited to the site of infection. The dissemination of MAP is thought by using 
macrophages as vehicles from the infected sites (Valentin-Weigand and 
Goethe, 1999). It has been shown in one study that MAP was able to 
disseminate from intestinal tissues into liver and lymph nodes. Both ileum and 
mesenteric lymph nodes were infected with MAP, albeit fecal shedding of MAP 
was not observed in this initial phase (Wu et al., 2007). 
 
Figure 1.4 Transmission electron micrograph of MAP in mouse intestine. 
Transmission electron micrograph from a mouse orally infected with MAP. MAP can be 
observed within enterocytes (arrows). Magnification, x10,000 (Bermudez et al., 2010). 
 
Cytokines and chemokines production was induced at the site of of infection. 
The adaptive immune system represented by CD4+ and CD8+ T cells were 
recruited to the site of infection and activated. This leads to inflammation and 
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granuloma formation. Granulomas were formed because the immune cells could 
not eliminate mycobacteria from infected macrophages.  These structures are 
established, because the immune cells were continuously recruited to the site of 
infection and try to restrict the bacteria from dissemination (Figure 1.5). 
 
Figure 1.5 The host cellular immune response during Mycobacteria infection. 
Summary of current knowledge in host cellular immune response against mycobacterial 
infection, starting from bacterial recognition, recruitment of innate immune cells, activation of 
adaptive immune system, inflammation and granuloma formation (Dorhoi et al., 2011). 
 
1.3.1 Early response to MAP infection 
The mechanisms how MAP can survive inside of macrophages are still poorly 
understood. However, monocytes infected with live MAP showed reduction of 
phagolysosome fusion in comparison to monocytes that had ingested killed 
MAP. In addition, one study showed that live MAP showed higher percentage of 
colocalization with LAMP-1 in comparison to heat-killed MAP within 
macrophages (Figure 1.6). This result showed that live MAP could delay the 
phagolysosome fusion (Ghosh et al., 2013). It also showed that Ca2+ and 
phosphatidylino 3-kinase dependent pathways are required for MAP elimination 
(Woo et al., 2007). Additionally, acidification and maturation of phagolysosome 
were increased in macrophages stimulated in vitro by IFN-γ and LPS. This leads 
to higher killing activity of the macrophages against MAP (Hostetter et al., 
2002).  Interestingly, MAP uses Jun N-terminal kinase/stress activated protein 
kinase pathway to regulate cytokines expression in bovine monocytes to inhibit 
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phagosome acidification (Souza et al., 2006). Therefore, MAP could survive and 
reside within the host cells. 
To activate the innate response to MAP, toll like receptors (TLRs) and 
nucleotide-binding oligomerization domain-containing protein 2 (NOD2) are 
important. One study showed that sonicated MAP can only be recognized by 
TLR2 in peripheral blood mononuclear cells (PBMCs), but not TLR4. In contrast, 
TLR4 is important to activated cytokines in live MAP infected human 
mononuclear cells. Furthermore, HEK cells transfected with NOD2 could be 
stimulated by sonicated MAP in dose-dependent manner, suggesting NOD2 to 
recognize MAP (Ferwerda et al., 2007). 
 
Figure 1.6 Confocal microscopic examination of MAP-lysosome colocalization. 
MAP could delay the maturation of phagolysosome. Blue, DAPI-stained nuclei; red, LAMP-1 
(marker for lysosome); green- auramine-stained MAP. Yellow showed co-localization of MAP 
and LAMP-1 (arrowhead) (Ghosh et al., 2013). 
 
1.3.2 Adaptive immune response to MAP infection 
Activation of adaptive immunity is also important for the elimination of MAP. 
Antigen presentation is initiating the adaptive immune response. After ingestion 
of MAP, antigen presenting cells (APC) express Major Histocompatibility 
Complex (MHC) class II molecules that present mycobacterial antigens (Sohal 
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et al., 2008). This then leads to the activation of specific CD4+ T cells. On the 
other hand, MHC class I molecules expressed in all nucleated cells present the 
antigen to activate specific CD8+ T cells. Both specific CD4+ and CD8+ T cells 
are important in elimination mycobacteria. MHC molecules are upregulated by 
pro-inflammatory cytokines such as IFN-γ, TNF-α and IL-1. Anti-inflammatory 
cytokines such as IL-10 can inhibit both MHC expressions. The productions of 
cytokines on the site of infections are also important for recruitment of T cells 
and other immune cells. Interestingly, MAP could downregulate the expression 
of MHC I and MHC II expression which leads to lower activation of T cells and 
higher survival of MAP (Weiss et al., 2001; Zur Lage et al., 2003). This could be 
because MAP can inhibit pro-inflammatory cytokines expression resulting lower 
expression of MHC. 
Granuloma is one of the hallmarks in mycobacteria infection. As described 
previously, formations of granulomas are considered as an accumulation of 
inflammatory mononuclear cells directed by T cells which capable of limiting 
growth of mycobacteria (Ehlers and Schaible, 2012). Macrophages, CD4+ and 
CD8+ T cells and other immune cells are consistently present in surrounding of 
MAP granulomas. In subclinical MAP infection, TNF-α induces MAP-infected 
macrophages and other cells to release cytokines and chemotactic factors 
including IL-8 and MCP-1 to the site of infection. This could maintain 
mycobacteriostasis within persistently infected macrophages and activation 
newly recruited macrophages at site of MAP infection. 
The humoral response to mycobacteria infection has beneficial effects to the 
host including prolonged survival, CFU reduction and antigen clearance. 
Efficient antigen processing and presentation of B cells to activate T cells 
against MAP infection could be significant for the early response. Recognition of 
MAP antigen by surface IgM  on B cells leads to clone specific activation and 
expansion which results in plasma cells producing MAP specific antibody  
(Sohal et al., 2008). In subclinical phase, antibody titers against MAP are only 
detected in mid to late stage, which is associated with increasing number of 
MAP detected in feces. At this stage of infection, anti-MAP antibodies of the 
IgG1 subclass is dominant (Whitlock and Buergelt, 1996).  
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1.4 Animal models of MAP infection 
Animal models are needed to experimentally study in more detail the host-
pathogen interaction, host immune response, and to evaluate vaccine 
candidates and therapeutics. Cattle, goats, sheep, cervids and mice have been 
used as animal models for previously described purpose in MAP infection. 
Although mouse models may not entirely reflect the disease in cattle, sheep and 
goats, it is beneficial to study MAP infection in this small animal model. The 
availability of distinct inbred strain as well as transgenic mice and knockout mice 
allows investigating pathogenicity of microorganism as well as defense 
mechanism of the host in more detail. The information acquired might lead to 
novel therapies.   
Many mouse experiments have been done with regard to MAP infection. A 
comparison of i.p infection in different mouse strains showed that BALB/c  were 
the most susceptible and C57BL/10 were the least susceptible (Chiodini and 
Buergelt, 1993). However, another study demonstrated that C57BL/6 mice are 
more susceptible than C3H/HeN mice after i.p infection (Veazey et al., 1996).  
None of these mouse strains could be infected orally. Oral infection was 
performed successfully in SCID/beige mice deficient in B, T and NK cells 
(Mutwiri et al., 1992). However, in one study using B-cell deficient mice that lack 
of Peyer’s patches it was demonstrated that MAP could translocate across the 
mucosal barrier via M cells and enterocytes (Bermudez et al., 2010). The 
reason why such experimentals leaded controversial results is unclear. 
Experimental set up or more likely bacterial strain differences could account for 
it.    
 
1.5 Aim of the work 
In general, little is known about the infection process of MAP, its persistence in 
the host and the elicited immune responses. To a large extend, this is due to the 
absence of an appropriate small animal model. Although mouse models for 
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MAP infection have previously been developed, a suitable model that reflects 
the situation in JD or even CD is still missing.  
Prompted by the controversy on the presence of MAP in intestinal tissues of CD 
patients as well as the ubiquitous exposure of humans to environmental MAP, it 
was hypothesized that MAP might not cause CD but rather exacerbate a 
preexisting intestinal inflammation. In JD, animals are usually infected with MAP 
early in life and have long disease progression from subclinical phase to the 
clinical phases. It has been discussed that MAP could survive in milk, soil and 
water which could be possible sources for MAP transmission.  Accordingly, it 
was hypothesized that infected animals will reveal the clinical JD symptoms 
after secondary exposure to MAP. This might be also the case in CD. Based 
upon both hypotheses; dextran sulfate sodium-induced colitis was combined 
with MAP infection in mice. A secondary challenge with MAP was also tested.  
The establishment of mouse infection model for MAP should give important 
hints to understand Johne’s disease in ruminants as well as the association 
between MAP and Crohn’s disease in human. It will allow establishing immune 
parameters and ultimately leading to the development of new treatment 
strategies for patients. 
 
 
Materials and Methods 
21 
 
 
2 Materials and Methods 
2.1 Bacterial strains and cultures 
Cultivation of bacteria was done at the University of Veterinary Medicine 
Hannover (TiHo). M. avium ssp. paratuberculosis (MAP) strain DSM 44135 was 
grown on Watson Reid medium supplemented with mycobactin J (1 mg/L) at 
370C (Kuehnel et al., 2001). M. avium ssp. avium (MAA) strain DSM 44156 or 
ATCC 25291 and M. avium ssp. hominissuis (MAH) strain 04A/1287 were 
grown in the same medium without mycobactin J. 
 
2.2 Mouse strains 
TLR2-/- and RAG2-/- mice were bred at the animal facility of the Helmholtz 
Centre for Infection Research (HZI) under specific pathogen-free conditions 
(SPF). C57BL/6J wild type mice were purchased from Janvier (Le Genest-saint-
Isle, France). Female mice aged between 8-10 weeks were used at the 
beginning of all experiments. Animal studies were carried out under good animal 
practice conditions in strict accordance with the German law for animal 
protection (Tierschutzgesetz, §7-9) from Okt.1. 2006. In particular, experimental 
procedures were performed under the approval of the ethics committee of the 
local authority, Niedersächsisches Landesamt für Verbraucherschutz und 
Lebensmittelsicherheit (LAVES). Permit number for this study is 
Nr.:33.14.42502-04/090/08. All efforts were made to minimize the number of 
animals used and their suffering. 
 
2.3 Induction of DSS induced colitis and MAP infection  
DSS treatment: 4% DSS (35-50,000 kDa; MP Biomedical) was administered via 
the drinking water from day 1 until day 5. For infection, mice were 
intraperitoneally (i.p) injected with 108 MAP, MAA or MAH in endotoxin free 
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Dulbecco’s phosphate-buffered saline (PAA) two days after DSS administration. 
This application route was chosen since oral application did not lead to 
reproducible infection rates in our hands. Body weight was monitored 2-3 times 
weekly.  
Mice were sacrificed at day 1 post infection (1d p.i.), 1 week post infection (1wk 
p.i.) and 3 week post infection (3wk p.i.). For secondary challenge, mice were 
re-injected at 5 week post infection (5wk p.i), and then were sacrificed at day 1 
after secondary challenge. The total weight of liver and spleen were measured 
and the organs were harvested for histology and homogenization for serial 
dilution and plating. The length of colon was measured, a 1-2 cm section was 
then separated for histology, and the rest was homogenized for plating after 
washing with PBS. Small intestine and mesentery were collected similarly for 
plating and histology.  
To deplete CD4 and CD8+ T cells, 150µg/mL anti-CD4 antibody (Clone GK1.5, 
Molecular Immunology, HZI), anti-CD8 (Clone 53-6.7, Molecular Immunology, 
HZI) or Rat IgG2b isotype control (eBR2a, eBioscience) were administered i.p 3 
days before secondary challenge. 
 
2.4 Organ plating  
Liver, spleen, colon, small intestine and mesentery tissues were homogenized 
with sterile PBS supplemented by 0.1% Triton-X100 (Sigma) with sterile 3 mm 
glass beads 2 times for 20 seconds using the homogenizer FastPrep-24 (MP 
Biomedicals). The liver, spleen and mesentery homogenates were plated on 
Middlebrook 7H10 agar (Difco TM) containing Mycobactin J (IDVet Innovative 
Technology). The colon and small intestine homogenates were also plated on 
Middlebrook 7H10 agar containing Mycobactin J and antibiotics (Vancomycin, 
5mg/mL, Roth; Amphotericin B, 39 mg/mL, Roth and; Nalidixin Acid, 10 mg/mL, 
Sigma). The plates were incubated at 37oC for up to 8 weeks. 
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2.5 Pathology and Histology 
Histology was performed in the Mouse Pathology platform at HZI Braunschweig. 
Organs were fixed in 10% formaldehyde, dehydrated with ethanol, and 
embedded in paraffin. Paraffin sections (0.5 µm) were stained with hematoxylin-
eosin (H&E) and Ziehl-Neelsen (ZN) staining according to standard laboratory 
procedures. Scoring of histopathological changes of both colon and mesenteric 
tissue was performed in a blinded fashion. For scoring of colonic tissue, a 
combined score of severity, ulceration, edema and area involved was applied. 
Grades applied for severity were 0 = no alteration, 1 = mild, 2 = moderate, 3 = 
severe alterations. For ulceration score, the graded were 0 = no ulcer, 1 = 1-2 
ulcers (involving up to a total of 20 crypts), 2 = 1-4 ulcers (involving a total of 20-
40 crypts) and 3 = any ulcers larger than 40 crypts. For edema score, the 
grades were 1 = only mild epithelial or submucosal edema, 2 = mild epithelial 
edema associated with mild submucosal edema or more moderate submucosal 
edema, and 3 = every edema more extensive that the previous. For area 
involved in the inflammatory process, the grades were 0 = 0%, 1 ≤ 30%, 2 = 
40%-70%, 3 ≥ 70%.  
For scoring of mesenteric tissue, only a combined score of severity, area 
involved and the existence of mycobacteria in ZN staining was applied. The 
severity and area involved were graded similar to the colon tissue. For the 
existence of mycobacteria in ZN staining, the grades were 0 = no bacteria, 1 = 
small amounts of bacteria, 2 = moderate amounts (clearly seen in 20x 
magnification), and 3 = high amounts (massive colonies were clearly seen in 
10x magnification). Granuloma, number and area, in liver section were analyzed 
in 0.2 cm2 fields per section and quantified using AxioVision software (Carl 
Zeiss, Germany). The following antibodies were used for immunohistochemistry 
of mesentery: Myeloperoxidase (Clone Ab-1, Medac), Mac-2 Antibody (M3/38, 
Biozole) and CD3 Antibody (SP7, Thermo Fischer Scientific). 
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2.6 Transmission electron microscopy 
Electron Microscopy was carried out in the imaging platform of the HZI. 
Mesenteric tissue were excised and fixed in with 2% glutaraldehyde/5% 
formaldehyde in HEPES buffer containing 10 mM MgCl2, 10 mM CaCl2 and 
0.09M sucrose, pH 6.9, for 1 hour on ice, washed with buffer, and further fixed 
with 1% aqueous osmium for 1 hour at room temperature. Samples were then 
dehydrated with a graded series of acetone (10, 30, and 50%). At the 70% 
dehydration step samples were left over night in 70% acetone containing 2% 
uranylacetate, and further dehydrated with 90% and 100% acetone. Samples 
were then embedded in the epoxy resin Spurr (hard formular) according to 
described procedures (Spurr, 1969). Ultrathin sections were cut with a diamond 
knife, picked up with butvar-coated grids, counterstained with uranyl acetate and 
lead citrate, and examined in a TEM 910 transmission electron microscope (Carl 
Zeiss, Oberkochen) at an acceleration voltage of 80 kV. Images were recorded 
digitally at calibrated magnifications with a Slow-Scan CCD-Camera (ProScan, 
1024x1024, Scheuring, Germany) with ITEM-Software (Olympus Soft Imaging 
Solutions, Münster, Germany). 
 
2.7 ELISA  
For collection of sera, blood was collected into Microvette 500 serum gel 
(Sarstedt), and then centrifuged for 5 minutes at 10000g in room temperature. 
The supernatants were collected and stored at -20 °C. For collection of intestinal 
lavage, small intestines were washed with 300 μl intestinal wash buffer (PBS 
including 0.1 mg/ml Trypsin-inhibitor, 50 mM EDTA, and 0.1 % BSA). The flow 
through was collected into 1.5 ml tubes, centrifuged for 10 min at 1000 rpm in 
room temperature. The supernatants were collected and stored at -80 °C. For 
colon supernatant, colon were flushed with cold PBS, opened along longitudinal 
axis, cut into 0.5 cm pieces and incubated for 24 h in RPMI 1640 supplemented 
with 10% FCS. Colon supernatant were collected and kept at -20oC.  
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Immunoglobulin (Ig) concentrations in intestinal lavage and sera and IFN-γ level 
in sera were measured using ELISA. In brief, goat anti-mouse IgA (Sigma), goat 
anti-mouse IgG (Sigma), rat anti-mouse IgM (BD Pharmingen) or rat anti-mouse 
IFN-γ (Molecular Immunology, HZI) in coating buffer were incubated in 96 well 
plates (MaxiSorb TM Immunoplates, Nunc) overnight at 4oC. The 96 well plates 
were then blocked for 1 hour, with 3% BSA in 0.05% Tween 20. Diluted 
sera/intestinal lavages were distributed to the wells and incubated for 2 hours at 
room temperature. Ig was detected with biotinylated rat anti-mouse IgA (Sigma), 
peroxidased goat anti-mouse IgG (Jackson Immunoresearch), biotinylated rat 
anti-mouse IgM (AbD Serotec) or biotinylated anti-mouse IFN-γ antibodies 
(Molecular Immunology, HZI). Biotinylated antibodies were bound with 
horseradish peroxidase (HRP) conjugated streptavidin (BD). Bound HRP was 
determined using o-Phenylendiamin (OPD) as substrate and the results were 
read using an ELISA-reader (BioRad 3550- UV microplate reader) at a 
wavelength of 490 nm.  
TNF-α level from sera and colon supernatant were detected using Mouse TNF-α 
ELISA kits (Biolegend) according to manufacturer’s protocol. Mouse cytokines 
and chemokines from sera were analyzed using Bio-plex Pro Mouse Cytokines 
23-plex Assay (Bio-Rad) according to manufacturer’s protocol. 
 
2.8 Flow cytometry 
Spleen cells were prepared by gently flushing the spleen with IMDM containing 
antibiotics (100 U/mL penicillin and 100 µg/mL streptomycin), 10% FCS, 50 µM 
β-ME, 2 mM L-glutamine. Cells from mesenteric lymph nodes were prepared by 
mechanical dissociation. Cells suspension was passed through 50 µm nylon 
filter. Red blood cells were lysed for 2 minutes in ACK buffer (0.15 M NH4Cl, 10 
mM KHCO3, and 0.1 mM EDTA) and were then blocked with 1 µg/mL FcR block  
(rat anti-mouse CD16/CD32, BD Pharmingen).  
Isolation of colonic lamina propria leukocytes were performed according to 
described procedure with slightly modification (Zigmond et al., 2012). In brief, 
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colons were flushed their luminal content with cold PBS, opened longitudinally 
and cut into 0.5 cm pieces and incubated 3x in HBSS (Ca and Mg free) with 5% 
FCS, 2mM EDTA, 1mM DTT and 10mM HEPES at 37oC shaking at 250rpm for 
15 minutes to remove epithelial cells and mucus. Tissue was then digested in 
RPMI 1640 with 10% FCS, 1.5 mg/mL collagenase type VIII, and 0.1mg/mL 
DnaseI at 37oC shaking at 250rpm for 45 minutes. Percoll (GE Healthcare) 
gradients using 40/80% were performed to purify the leukocytes.  
The following antibodies were used for flow cytometry analysis: anti-CD45 APC-
Cy7 (30-F11, Biolegend), anti-CD3 FITC (17A2, eBioscience), anti-CD4 
APCeFluor780 or APC (RM4-5, eBioscience), anti-CD11c Pe-Cy7  or FITC 
(N418, eBioscience), anti-CD19 APC or PerCP-Cy5.5 (1D3, BD Pharmigen), 
anti-CD8 PerCP-Cy5.5 or PE (53-6.7, eBioscience), anti-Ly6C APC (AL-21, BD 
Pharmigen), anti-Gr-1 APC-Cy7 (RB6-8C5, BD Pharmigen), anti-Ly6G PE-Cy7 
(1A8, Biolegend), anti-F4/80 PerCP-Cy5.5 (BM8, eBioscience) and anti-CD11b 
FITC or PE (M1/70, eBioscience). DAPI (Sigma) were used for live and dead 
discrimination.  
To quantify MAP binding IgG, IgM and IgA antibodies, a similar volume 
containing 108 CFU/mL MAP and serum were mixed and incubated for 30 
minutes. The bacteria were washed in PBS/5mM EDTA/2% FCS before 
resuspension in anti-IgM PE (BD Pharmingen), anti-IgG FITC (Caltag lab) or 
anti-IgA Biotin (Maltechab). Flow cytometry was performed using a LSR II 
analyzer (BD, NJ, USA). The data were analyzed using FACSDiva software 
(BD) and FlowJo (TreeStar). 
 
2.9 Quantitative Real Time PCR 
RNA from colon tissues was isolated with RNeasy Mini kit (Qiagen) according to 
manufacturer’s protocol. cDNA synthesis was performed using Revert Aid First 
Strand cDNA Synthesis Kit (Fermentas) according to manufacturer’s protocol. 
Power SYBR® Green PCR Master Mix (AB Applied Biosystems) was used 
according to the manufacturer’s instructions. The following primers were used 
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for quantitative PCR: 5’-TGG GAG TAG ACA AGG TAC AAC CC-3’, 5’-CAT 
CTT CTC AAA ATT CGA CTG ACA A-3’ for TNF-α; 5’-TTG ACG GAC CCC 
AAA AGA TG-3’, 5’-AGA AGG TGC TCA TGT CCT CA-3’ for IL-1β; 5’-TGG 
CTC TGC AGG ATT TTC ATG-3’,5’-TCA AGT GGC ATA GAT GTG GAA GAA-
3’ for IFN-γ; 5’-CTG GAC AAC ATA CTG CTA ACC GAC TC-3’, 5’-ATT TCT 
GGG CCA TGC TTC TCT GC-3’ for IL-10; 5′-CTG GAC GAG GGC AAG ATG 
AAG C-3′, 5′-TGA CGT TGG CGG ATG AGC ACA-3′ for ribosomal protein S9 
(RPS9) as standard. Relative fold changes were normalized against 
housekeeping gene RPS9. qRT-PCR were performed on 7500 Real Time PCR 
System (Applied Biosystem). 
 
2.10 Measurement of fluid absorption in colon 
Fluid absorption measurement was performed at Department of 
Gastroenterology, Hepatology, and Endocrinology, Hannover Medical School 
according to previously published protocol (Singh et al., 2010). Animals had free 
access to food and water before the experiment. Induction of anesthesia was 
achieved by spontaneous inhalation of isoflurane (Forene; Abbott Germany, 
Wiesbaden, Germany). The inhalation gas contained a mixture of ~10–15% 
oxygen, ~85–90% air, and ~2.0 ± 0.2% isoflurane with the use of an isoflurane 
pump (Univentor 1250 Anaesthesia Unit; AgnTho, Lidingö, Sweden) and was 
administered continuously through a breathing mask. The depth of the 
anesthesia was tested by probing the pedal withdrawal reflex and breathing rate 
of the mice. The gas flow through the cylindrical mask (2 cm long with an inner 
diameter of 1.2 cm) was ~200 ml/min, which minimized rebreathing of exhaled 
CO2 by the animals. To minimize the anesthesia level and pain during surgery, 
all the mice received subcutaneous injection of 500 mg/kg body weight of 
Novalgin 30 min. before the surgery was started. Body temperature was 
maintained using a heating pad. A catheter was placed in the left carotid artery 
for continuous infusion of (in mM) 200 Na+ and 100 CO3
−2 at a rate of 0.30 ml/h 
to prevent anesthesia induced acidosis. Lower abdomen was opened by one 
small central incision, and whole colon was used for measurement. A small 
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polyethylene tube (PE100) with a distal flange was advanced into the proximal 
colon through an opening in cecum and secured by a ligature that served as an 
inlet tube. PE200 flanged tubing was secured by ligature to allow for drainage 
through the anus in the distal part of the colon. The isolated colonic segment 
with an intact blood supply was gently flushed and then perfused (Perfusor 
compact; BRAUN, Bethlehem, PA, USA) at a rate of 3 ml/h with 150 mmol/l 
NaCl. Effluents from the isolated segment were visually free of blood throughout 
all experiments. After an initial 30-min. washout and recovery period, fluid 
absorption was measured for another 1 hour. At the end of the experiments, 
mice were killed by cervical dislocation. The perfused segment was excised 
from in situ position, and its length was measured. The perfusate was collected 
in a pre-weighed 4.5-ml collecting tube. After a 30-min period, the tube was 
weighed again and the difference of the two up to four places of decimal was 
taken as the amount of fluid recovered after 30 min (taking density of fluid 
roughly at about 1 g/ml). The difference was further subtracted from 1.5 ml, 
which was the original volume recovered after 30 min. in case of no fluid 
absorption. All values were represented in milliliters of fluid absorbed per 
centimeter colon length per hour (ml/cm/h). 
 
2.11 Statistics 
All data were analyzed with GraphPad Prism software. In some figures 
statistical difference between groups were determined by 1-way Anova and 
followed by Tukey’s multiple comparison tests. In some figures statistical 
difference between groups were determined by Student t-test. The data 
considered statistically significant when p values were less than 0.05. * = p 
values < 0.05, **=  p ≤ 0.01,***= p < 0.001, n.s = not significant.  
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3 Results 
All the following experiments were carried out under the premises that a MAP 
infection will exacerbate an existing inflammation in the gut. Thus inflammatory 
bowel disease was chemically induced in mice and the animals were 
subsequently infected intraperitoneally (i.p) with MAP. 
3.1 MAP infection after colitis induction  
In the drinking water of adult female C57BL/6J mice, 4% DSS was added from 
day 1 until day 5. After two treatment-free days, 108 MAP were injected i.p. The 
experimental schedule is illustrated in Figure 3.1A. Body weight was measured 
as a read out for the general health condition (Figure 3.1B). Mice infected with 
MAP only (H2O+MAP) showed reduction of body weight at 1 day p.i. and started 
to regain weight at 2 days p.i.. In contrast, both MAP infected (DSS+MAP) and 
non-infected DSS pretreated mice (DSS+PBS) started to lose weight after DSS 
administration and showed bloody diarrhea.  
A 
 
Figure 3.1 Experimental set-up and body weight measurement.   
A. Overview of the experimental schedule. H2O or 4% DSS were administered to the drinking 
water from day 1 until day 5, followed by normal drinking water afterwards. PBS or 10
8 
CFU 
MAP in 200 µL i.p. was administered two days after DSS treatment finished (day 0). Mice were 
sacrificed at day 1, 1 week and 3 weeks p.i.. B. Weight change during experiment, expressed as 
percentage change from day 1 of DSS treatment. The results shown are representative of more 
than three independent experiments (n= 5-15). 
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Dramatically elevated levels of cytokines were observed in the serum of mice 
after MAP administration (Figure 3.2 and Table 3.1). Interestingly, the kinetic of 
enhanced cytokine levels differed between H2O+MAP and DSS+MAP mice. 
H2O+MAP mice showed higher TNF-α serum level at 2 hours and 6 hours after 
infection than DSS+MAP mice but decreased to normal at 24 hours p.i.. 
Conversely, levels of TNF-α in DSS+MAP mice remained constitutively 
increased until 24 hours p.i. (Figure 3.2). These results suggest that a 
differential response to MAP infection takes place between untreated and DSS-
treated mice. The DSS+PBS group showed low TNF-α serum level and 
H2O+PBS control group showed TNF-α serum level below detection limit. 
 
Figure 3.2 Kinetics of TNF-α serum level from 2, 6 and 24 hours post infection.  
At 2h and 6h p.i., TNF-α serum level was significantly higher in H2O+MAP (2h = *, 6h = **) and 
DSS+MAP (2h = ***, 6h = **) group in comparison to DSS+PBS. TNF-α serum level of 
H2O+MAP showed higher at 2h (*) and 6h (***) p.i. in comparison to DSS+MAP. At 24h p.i., 
DSS+MAP showed higher TNF-α serum level then H2O+MAP (*) and DSS+PBS (**).  H2O+MAP 
and DSS+PBS showed no different TNF-α serum level at 24h p.i. TNF-α serum level of 
H2O+PBS was below detection limit. The results shown are representative of at least two 
independent experiments (n=3-5). *p<0.05, **p<0.01, ***p<0.0001. 
 
3.2 Enlargement of spleen and liver in DSS+MAP mice  
At 1 week p.i., DSS+PBS, H2O+MAP and DSS+MAP mice showed higher total 
spleen weight compared to H2O+PBS mice. This effect was most pronounced in 
DSS+MAP mice. Such mice exhibited significantly more enhanced spleen 
weight at 3 weeks p.i. compared to H2O+MAP or DSS+PBS mice (Figure 3.3A). 
Similarly, a significant enlargement of the liver was observed in DSS+MAP mice 
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at 3 weeks p.i. (Figure 3.3B). Independent of MAP infection, DSS treated mice 
displayed a significant shortening of the colon length at 1 day p.i. but had 
recovered by 1 week p.i. (Figure 3.3C).  
 
 
Figure 3.3 Measurement of total spleen and liver weight and colon length  at 1d, 1 
week and 3 weeks p.i.  
A. Total spleen weight in Gram. B. Total liver weight in Gram. C. Colon lengths in cm. Data are 
representative of at least three independent experiments (n=3-15). *p<0.05, **p<0.01, 
***p<0.0001 
 
3.3 Cellularity of spleen  
The significant enlargement of the spleen observed at 1 and 3 weeks p.i. in 
DSS+MAP treated mice was not accompanied by a significant enhancement of 
bacterial organ counts (Figure 3.4A). Since the enlargement of spleen tissue 
was most likely due to the immigration or accumulation of immune cells we 
analyzed the composition of splenic cells at 3 weeks p.i. by flow cytometry. 
Polymorphonuclear cells (PMN; CD11b+Gr1hiLy6Cint) and monocyte 
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(CD11b+Ly6ChiGr1int) numbers were higher in DSS+MAP compared to 
H2O+PBS and H2O+MAP spleen tissue but similar to DSS only treated animals 
(Figure 3.4B-C). The elevation of the myeloid compartment was therefore most 
likely induced by the DSS induced damage of the colon. Penetration of the 
intestinal mucosal barrier and spread of commensal bacteria from the enteric 
microbiota might be responsible for the inflammatory response observed in the 
spleen. We could not see any difference in lymphocytes population between the 
groups examined (data not shown).  
 
 
Figure 3.4 DSS+MAP treated mice show an increase in splenic PMN and monocyte 
population.  
A. Bacterial loads in spleen were analyzed at 3 weeks p.i. by plating tissue on Middlebrook agar 
(n=3-9). B-C. Spleen cells were isolated and stained with DAPI and analyzed by Flow cytometry. 
B. Total number of PMN (CD11b
+
Gr1
hi
Ly6C
int
). C. Total number of monocyte 
(CD11b
+
Ly6C
hi
Gr1
int
). Data are representative of at least two independent experiments (n=3-5). 
*p<0.05, **p<0.01, n.s = not significant. 
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3.4 Increased granuloma formation in the liver of DSS+MAP 
mice 
To understand the underlying cause of the liver enlargement in DSS+MAP mice 
at 3 weeks p.i. (Figure 3.3B), a detailed analysis was carried out. Severe 
granuloma formation was observed in both infected groups by histological 
examination, which was never found in uninfected animals (Figure 3.5A-B). 
Granuloma formation represents the histopathological hallmark of mycobacterial 
infection in general and represents both protective immunity and inflammatory 
tissue destruction. Strikingly, number (Figure 3.6A) and size of granulomas 
(Figure 3.6B) in DSS+MAP mice were significantly enhanced compared to 
H2O+MAP mice. More polymorphonuclear cells (PMN) and macrophages were 
visible in these areas in the DSS+MAP group (Figure 3.5B). Even though, no 
significant difference in CFU/g liver between H2O+MAP and DSS+MAP mice 
could be observed (Figure 3.6C). Despite granuloma formation, MAP could be 
hardly visualized in liver tissue using Ziehl Neelsen staining (data not shown). 
This might be due to the low number of total MAP in liver. An enhanced 
immunoreactivity of the liver tissue, however, could be detected in DSS+MAP 
mice illustrated by the enhanced frequency and extent of granuloma formation. 
 
3.5 Elevated antibody levels in DSS+MAP mice 
Since a marked immune activation was observed in mice treated with DSS and 
infected with MAP, we next wanted to know whether an antibody response was 
induced under these circumstances. Therefore, we monitored the 
immunoglobulin levels in serum and intestinal washing fluid at 1 day, 1 week 
and 3 weeks p.i. Total serum IgM increased over time in all groups which was 
most likely due to the increasing age of the animals (Figure 3.7A). Nevertheless, 
there were no differences in serum IgM level in all of the groups. In addition, 
flow cytometry-based quantification of MAP specific IgM antibodies showed no 
significant difference between the groups examined (Figure 3.7C). 
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Figure 3.5 H&E staining of liver tissue sections at 3 weeks p.i.  
A. Normal liver tissue (20x magnification) was observed in H2O+PBS (left) and DSS+PBS 
(right). Scale bars, 50 µm. B. Granuloma formation (black arrow) was observed in infected mice 
H2O+MAP (upper left) and DSS+MAP (upper right) in 20 x magnifications. Scale bars, 50 µm.  
Larger granuloma was observed in DSS+MAP (bottom right) compares to H2O+MAP (bottom 
left) in 40x magnifications. Scale bars, 100 µm. 
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Figure 3.6 Histological determination of granuloma numbers and size and bacterial 
loads in liver at 3 weeks p.i.  
A. Number of granuloma in an area 0.2 cm
2
. B. Size of granuloma, expressed in µm
2
 (n=3-5) C. 
Bacterial loads in liver were analyzed at 3 weeks p.i. by plating tissue on Middlebrook agar. Data 
are representative of at least two independent experiments (n=3-11). *p<0.05, n.d = not 
detectable. 
 
In a similar fashion, total serum IgG levels also increased over the time in all 
groups (Figure 3.7B). However, at 1 day p.i., animals of the DSS+PBS, 
H2O+MAP and DSS+MAP groups showed significantly lower total serum IgG 
levels in comparison to mice of the H2O+PBS group. These results might be due 
to inflammation elicited by DSS treatment and/or MAP infection in line with the 
observed reduced body weight. However, at 1 week p.i. total serum IgG level in 
all groups showed similar levels. Interestingly, at 3 weeks p.i. only animals of 
the DSS+MAP group showed significantly higher (p<0.05) total serum IgG levels 
as compared to H2O+PBS and DSS+PBS animals. Additionally, MAP specific 
IgG levels in animals of the DSS+MAP group were significantly elevated 
(p<0.01) as compared to uninfected animals (Figure 3.7D). In contrast, total 
intestinal IgA and total serum IgA were not significantly altered (Figure 3.7E-F). 
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Thus, the inflammation associated with DSS-treatment led to an increase in total 
serum IgG levels, and also to a significant increase of MAP specific IgG. 
 
3.6 Colonization of mesenteric tissue and granuloma 
formation by MAP  
In our mouse model, viable MAPs were found in liver (Figure 3.6C), spleen 
(Figure 3.4B) and intestine (see below) although at relatively low numbers. 
Colonization of the mesenteric tissue was previously postulated to explain 
inconsistencies of MAP detection in mucosal biospies from CD patients. 
Therefore, we investigated the possibility of colonization of mesenteric tissue by 
MAP under our experimental conditions. Indeed, high numbers of viable MAP 
could be detected by serial dilution platings of homogenized mesenteric tissue 
from MAP infected mice 3 weeks p.i (Figure 3.8A). Evidently, the MAP 
colonization led to accumulation of extremely high numbers of inflammatory 
cells which resulted in severe granuloma formation, tissue destruction and 
necrosis (Figure 3.8C). This was illustrated by the elevated histopathological 
score in both MAP infected groups (Figure 3.8B). Accumulation of neutrophils, 
macrophages and T cells in granulomas could be observed by 
immunohistochemistry in mesenteric tissue (Figure 3.9). Additionally, 
transmission electron microscopy demonstrated MAP inside host cells of the 
mesenteric tissue most likely representing macrophages (Figure 3.10).  
Colonization of the mesenteric tissue by MAP was not significantly different in 
the DSS treated and untreated group (Figure 3.8A). Similarly, the histological 
score did not reveal any significant difference between both groups (Figure 
3.8B). Importantly, no tissue alterations were found in DSS+PBS mice (data not 
shown). Thus, DSS treatment appears not to influence bacterial colonization 
and destruction of the mesenteric tissue. Taken together, the colonization of 
mesenteric tissue by MAP attracted immune cells, which subsequently led to 
severe granuloma formation. 
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Figure 3.7 Elevated antibody levels in DSS+MAP mice.  
A. Total serum IgM, B. Total serum IgG  at day 1, 1 week and 3 weeks p.i. were determined by 
ELISA. C. Mean fluorescence intensity (MFI) IgM and D. IgG bound MAP at 3 weeks p.i. was 
determined by flow cytometry. E. total serum IgA. F. total intestinal washout IgA at day 1, 1 
week and 3 weeks p.i. were determined by ELISA. Data are representative from at least two 
independent experiments (n=3-5). *p<0.05, **p<0.01, ***p<0.0001, n.s = not significant. 
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Figure 3.8 MAP was found in mesenteric tissue generating granuloma.  
A. Bacterial loads in mesentery were analyzed at 3 weeks p.i. by plating tissue on Middlebrook 
agar (n=3-8). B. Histology changes in mesentery were analyzed at 3 weeks p.i.(n=3-5). n.s = not 
significant, n.d = not detectable. C. H&E staining and Ziehl-Neelsen staining (ZN) of mesentery 
at 3 weeks p.i. MAP infected showed granuloma and huge number of inflammatory cells in 5x 
(upper left) and 20x magnifications (upper right). ZN staining of mesentery at 3 weeks p.i. 
showed positive ZN staining in MAP infected group in 5x (bottom left) and 20x magnifications 
(bottom right). Scale bars, 200 µm (5x) and 50 µm (20x). 
 
 
 
A B 
C 
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Figure 3.9 Immunohistochemistry in mesenteric tissue.  
Accumulation of macrophage (upper), T cells (middle) and neutrophils (bottom) in mesentery 
were observed at 3 weeks p.i. in MAP infected group by immunohistochemistry (5x 
magnification in left, 20x magnification in right). Neutrophils (brown), Macrophage (brown) and T 
cells (red) were visualized by anti-myeloperoxidase (MPO), anti-Mac-2 and anti-CD3.  M = T 
cells and Macrophage zone, N = Neutrophils zone, B = MAP zone. Scale bars, 200 µm (5x) and 
50 µm (20x). 
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3.7 Cellularity of mesenteric lymph nodes 
The mesenteric lymph nodes (mLN) are located in the mesenteric tissue and 
drain the intestine. In order to investigate changes in the cellular composition of 
mLNs following MAP infection or DSS treatment, we analyzed the immune cells 
in mLN by flow cytometry at 3 weeks p.i. DSS treatment alone resulted in 
immigration or accumulation of different types of immune cells in the mLN. 
Interestingly, reduced numbers of CD4+ and CD8+ T cells were found in mLNs 
of DSS+MAP animals as compared to DSS+PBS mice (Figure 3.11). Similar 
results were obtained for macrophages (CD11b+Gr1loLy6Clo). 
This finding might be explained by retention or death of migratory cells by the 
presence of MAP in the mesenteric tissue. Conversely, monocytes and 
granulocytes were found in higher numbers in DSS+MAP mice compared to 
DSS+PBS. Additionally, dendritic cells and B cells were found to be increased in 
both DSS treated groups. Together, DSS treatment increases the number of 
various immune cell populations in mLN but T cell and macrophage proliferation 
or migration are impaired as a consequence of MAP infection. 
 
 
Figure 3.10 Transmission electron microscopic pictures from mesenteric tissue.  
TEM visualized mesentery of MAP infected mice at 3 weeks p.i. MAP (white arrowheads) were 
residing inside of macrophage in both H2O+MAP (left) and DSS+MAP group (right). Collagen 
fibers (black arrow) were also observed. Scale bars, 2µm. 
 
 
Results 
41 
 
3.8 Tropism of MAP to the DSS-treated colon  
MAP is known to elicit overt clinical disease in ruminants only after a period of 
latency. Also, the organ tropism of MAP for the intestinal mucosa is 
mechanistically still unclear. Hence, we investigated the colonization of MAP in 
the inflamed colon under our experimental conditions. MAP colonization of colon 
tissue was significantly higher (p<0.05) following DSS treatment (Figure 3.12A). 
In contrast, only a non-significant colonization was found in the small intestine 
(Figure 3.12B). This may be explained by the fact that DSS primarily damages 
the colonic mucosa (Wirtz et al., 2007). Bacteria apparently are being attracted 
to the damaged mucosal tissue.  
Epithelial cell injury after DSS treatment leads to a severe intestinal pathology in 
the colon. Both DSS-treated groups (DSS+PBS and DSS+MAP) showed high 
histopathological scores at day 1 p.i.. The score was reduced at 1 week and 
was even less at 3 weeks p.i.. Strikingly, the colon score of DSS+MAP mice was 
significantly higher (p<0.05) than the score found in DSS+PBS mice at the 3 
weeks p.i.. This could be explained by delayed recovery of the colon mucosa 
due to MAP colonization (Figure 3.13A). At that time point, H&E staining of 
tissue obtained from DSS+MAP animals revealed moderate infiltration of 
inflammatory cells and mild epithelial hyperplasia, whereas tissue of DSS+PBS 
animals only showed low infiltration of inflammatory cells (Figure 3.13B).  
In line with the results from the histopathological score, colon tissue of 
DSS+MAP animals showed significantly higher mRNA levels of IFN-γ (Figure 
3.14) in comparison to H2O+PBS (p<0.001), DSS+PBS (p<0.01) and H2O+MAP 
(p<0.01) animals. Interestingly, similar results were also obtained for mRNA of 
the anti-inflammatory marker IL-10. In contrast, mRNA expression of IL-1ß was 
increased in colon tissue of all treated groups, DSS+PBS, H2O+MAP and 
DSS+MAP in comparison to H2O+PBS group. Additionally, mRNA expression of 
TNF-α and IL-6 (data not shown) showed no significant difference between the 
groups. Taken together, the toxic effect of DSS treatment on the colonic mucosa 
resulted in higher MAP colonization and delayed tissue recovery possibly due to 
a higher inflammatory response. 
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Figure 3.11 Cellularity of mesenteric lymph nodes.  
mLN were isolated and stained with DAPI and analyzed by Flow cytometry at 3 weeks p.i. Total 
number of CD4
+
 (CD3
+
CD4
+
) and CD8
+
 (CD3
+
CD8
+
) T cells, CD19
+
 B cells, dendritic cells 
(CD11b
+
CD11c
hi
), PMN (CD11b+Gr1
hi
Ly6C
int
), monocytes (CD11b
+
Ly6C
hi
Gr1
int
) and 
macrophage (CD11b
+
 Gr1
lo
 Ly6C
lo
) were quantified. Data are from two independent experiments 
(n=4-5). *p<0.05, **p<0.01, ***p<0.0001, n.s = not significant. 
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Figure 3.12 MAP had better survival in DSS-induced colon.  
A. Bacterial loads in colon and B. small intestine were analyzed at 3 weeks p.i. by plating tissue 
on Middlebrook agar with antibiotics. Data are representative of at least three independent 
experiments (n=3-11). *p<0.05, **p<0.01, ***p<0.0001, n.s = not significant, n.d = not 
detectable. 
 
3.9 MAP secondary challenge leads to diarrhea and colitis  
As above, 4% DSS was administered in the drinking water of adult female 
C57BL/6J mice from day 1 until day 5. After two treatment-free days, 108 MAP 
were injected intraperitoneally. Secondary challenge with 108 MAP i.p was 
performed at 5 weeks after first challenge. The five weeks time point was 
chosen to assure that mice have recovered from MAP first challenge and DSS 
treatment. The experimental schedule is illustrated in Figure 3.15A. Body weight 
was measured as a read out for the general health condition (Figure 3.15B). 
DSS-treated mice infected with MAP for the second time (DSS+MAP+MAP) 
showed reduction of body weight significantly in comparison to both uninfected 
DSS-treated (DSS+PBS+PBS) and untreated (H2O+PBS+PBS) at day 1 after 
second challenge. They started to regain weight at 4 days after secondary 
challenge. In contrast, DSS-treated mice infected with MAP for the first time 
(DSS+PBS+MAP) showed reduction of body weight at 1 day p.i and recovered 
at day 2 p.i. (Figure 3.15C). Extended weight recovery was also observed in 
mice without DSS treatment in mice infected with MAP for the second time 
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(H2O+MAP+MAP) in comparison to mice without DSS treatment MAP infected 
for the first time (H2O+PBS+MAP). 
 
 
Figure 3.13 MAP showed delayed recovery of DSS-induced colon.  
A. Histology changes in the colon were analyzed at day 1, 1 week and 3 weeks p.i. B. H&E 
staining of colon tissue sections at 3 weeks p.i. Scale bars, 25 µm. H2O+PBS (upper left) and 
H2O+MAP (bottom left) showed normal tissue. DSS+MAP (bottom right) showed mild invasion of 
A 
B 
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inflammatory cells (black arrow) and mild epithelial hyperplasia. DSS+PBS showed low invasion 
of inflammatory cells. Data are representative of at least two independent experiments (n=4-5). 
*p<0.05, **p<0.01, ***p<0.0001, n.d = not detectable. 
 
 
Figure 3.14 Higher inflammatory response in DSS-induced MAP infected mice at 3 
weeks p.i. 
mRNA expression of IFN-γ (upper left), IL-10 (upper right), TNF-α (bottom left) and IL-1β 
(bottom right) relative to RPS9 from colon at 3 weeks p.i. (n=4-5). *p<0.05, **p<0.01, n.s = not 
significant, n.d = not detectable. 
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Figure 3.15 Experimental set-up and body weight monitoring.  
A. Overview of the experimental schedule. H2O or 4% DSS were administered to the drinking 
water from day 1 until day 5, followed by normal drinking water afterwards. PBS or 10
8 
CFU 
MAP in 200 µL i.p. was administered two days after DSS treatment finished (day 0). At 5 weeks 
p.i, PBS or 10
8 
CFU MAP in 200 µL was administered i.p.. Mice were sacrificed at day 1 after 
secondary challenge. B. Weight change during experiment, C. weight change after secondary 
challenge, expressed as percentage change from day 1 of DSS treatment. C. The graph shown 
is only from 5 week after first challenge. The results shown are representative of more than 
three independent experiments (n=4-5). 
 
Interestingly, both MAP infected group H2O+MAP+MAP and DSS+MAP+MAP 
showed reduction of fluid absorption in colon which is a sign of mild diarrhea at 
day 1 after secondary challenge (Figure 3.16A). Strikingly, reduction of colon 
length was observed only in DSS+MAP+MAP mice at day 1 after secondary 
challenge which can be taken as a sign of colitis (Figure 3.16B). Additionally, 
the colon histology score of DSS+MAP+MAP mice was significantly higher than 
the score found in DSS+PBS+PBS mice at day 1 after secondary infection 
(Figure 3.16C). At that time point, H&E staining of tissue obtained from 
DSS+MAP+MAP animals revealed high infiltration of inflammatory cells and 
severe epithelial hyperplasia, whereas tissue of DSS+PBS+PBS and 
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H2O+MAP+MAP animals only showed low infiltration of inflammatory cells 
(Figure 3.17). These results suggest that there is a different immune response 
between first and second infection. DSS-treated MAP infected mice showed 
stronger immune response after secondary infection. This can be concluded 
from diarrhea, reduction of colon length and high histology score of the colon.  
 
 
Figure 3.16 MAP secondary challenge leads to diarrhea and colitis.  
Fluid absorption from colon in mL x cm
-1 
x hours
-1 
 (n=5). B. Upon the autopsy at one day after 
secondary challenge, colon length was measured. Colon lengths in cm (n=3-5) C. Histology 
score of the colon were analyzed at one day after secondary challenge (n=3-5). Graph show a 
representative of at least two independent experiments. *, P<0.05; **, p<0.01; ***,p<0.001, n.s = 
not significant, one-way ANOVA with Tukey’s post test. 
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Figure 3.17 H&E staining colon tissue section at day 1 after secondary challenge.  
H&E staining of colon tissue sections at day 1 after secondary challenge. Scale bars, 25 µm. 
H2O+PBS+PBS (upper left) showed normal tissue. H2O+MAP+MAP (bottom left) and 
DSS+PBS+PBS (upper right) showed low infiltration of inflammatory cells (black arrow). 
DSS+MAP+MAP (bottom right) showed high invasion of inflammatory cells (black arrow) and 
severe epithelial hyperplasia.  
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3.10 Elevated cytokines level after secondary challenge 
Since a marked immune response was observed in mice after secondary 
challenge, it was interesting to know whether cytokines and chemokines were 
induced under these circumstances. Therefore, we collected sera and pooled 
them from each group at 6 hours after secondary challenge and measured the 
cytokines and chemokines levels using cytokines and chemokines multiplex 
assay. Interestingly, nearly all cytokines and chemokines were upregulated in 
both H2O+MAP+MAP and DSS+MAP+MAP groups (Table 3.2).  
To confirm the result, we collected sera at 2, 6 and 24 hours after secondary 
challenge. Dramatically elevated levels of TNF-α were observed at 2 hours after 
secondary challenge in both H2O+MAP+MAP and DSS+MAP+MAP groups 
(Figure 3.18A). The TNF-α levels decreased gradually afterwards. IFN-γ levels 
elevated at 2 hours, reached the peak at 6 hours and decreased at 24 hours 
after secondary challenge (Figure 3.18B). The same kinetics of TNF-α and IFN-
γ levels were also observed from colon supernatant (Figure 3.18C-D). 
 
3.11 DSS+MAP treated mice exhibit increased leukocytes in 
mLN 
The mesenteric lymph nodes (mLN) are located in the mesenteric tissue and 
drain the intestine. In order to investigate changes in the cellular composition of 
mLNs following MAP infection and/or DSS treatment, mLN leukocytes were 
stained and analyzed by flow cytometry at day 1 after secondary challenge. The 
gating strategy was shown in Figure 3.19.  
Interestingly, the frequency of CD19+ B cells, dendritic cells (CD11b+CD11chi) 
and PMN (CD11b+Ly6GhiLy6Clo) were increased in DSS+MAP+MAP group in 
comparison to other groups, which has not been observed in H2O+MAP+MAP 
group (Figure 3.20). The increasing composition of those cells is caused by 
secondary challenge, since there was no increasing composition of those cells 
in DSS-treated infected MAP which did not receive a secondary challenge 
(DSS+MAP+PBS). 
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Figure 3.18 Elevated cytokines level after secondary challenge.  
Kinetics of TNF-α (A&C) and IFN-γ (B&D) at 2, 6 and 24 hours after secondary challenge (n=3-
5). (A-B) Cytokines level in serum (C-D) Secretion of cytokines into the supernatant of overnight 
cultured from colon. n.d = not detectable.  
 
For inflammatory monocytes (CD11b+Ly6ChiLy6Gint) and macrophages 
(CD11b+Ly6GloLy6CloF4/80hi), increased frequency were observed in 
DSS+MAP+MAP in comparison to H2O+PBS+PBS group. Additionally, no 
difference was seen between all groups in CD4+ and CD8+ T cells (Figure 3.20).  
However, the total cell numbers were found to be increased in both 
DSS+MAP+MAP and DSS+MAP+PBS. This leads to increase all leukocytes 
populations such as B cells, dendritic cells, inflammatory monocytes, PMN, 
macrophages, CD4+ and CD8+ T cells (Figure 3.21). Thus, combination of DSS 
treatment and MAP infection cause an increase in the number of cells in mLN.   
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Figure 3.19 Flow cytometry gating strategy for myeloid cells and lymphocytes from 
mLN and colonic lamina propria. 
Myeloid cells from live cells, CD45
+
 and CD11b
+
 consist of dendritic cells (CD11b
+
 
CD11c
hi
),PMN (CD11b
+
Ly6G
hi
Ly6C
int
), inflammatory monocytes (CD11b
+
Ly6C
hi
Ly6G
int
) and 
macrophages (CD11b
+
Ly6G
lo
Ly6C
lo
F4/80
hi
). Lymphocytes from live cells, CD45
+
 consist of 
CD19
+
 B cells, CD4
+
 (CD3
+
CD4
+
) and CD8
+
 (CD3
+
CD8
+
) T cells. 
 
3.12 Role of CD4+ T cells in DSS+MAP mice colon after 
secondary challenge 
To understand the underlying cause of reduction of colon length in 
DSS+MAP+MAP mice after secondary challenge described above, a detailed 
analysis of colon leukocytes composition was carried out by flow cytometry. The 
gating strategy was shown in Figure 3.19. No difference could be observed in 
CD8+ T cells, CD19+ B cells, macrophages (CD11b+Ly6GloLy6CloF4/80hi) and 
dendritic cells (CD11b+CD11chi) (Figure 3.22). Interestingly, CD4+ T cells 
showed significantly high frequency only in DSS+MAP+MAP in comparison to 
all other groups (Figure 3.22).   
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Figure 3.20 Frequency of leukocytes in mLN at day 1 after secondary challenge. 
Frequency of CD19
+
 B cells, CD4
+
 (CD3
+
CD4
+
) and CD8
+
 (CD3
+
CD8
+
) T cells. dendritic cells 
(CD11b
+
 CD11c
hi
),PMN (CD11b
+
Ly6G
hi
Ly6C
int
), inflammatory monocytes (CD11b
+
Ly6C
hi
Ly6G
int
) 
and macrophages (CD11b
+
Ly6G
lo
Ly6C
lo
F4/80
hi
) in mesenteric lymph nodes (n=3-5). Graph 
show a representative of at least two independent experiments. *, P<0.05; **, p<0.01; 
***,p<0.001, n.s = not significant, one-way ANOVA with Tukey’s post test. 
 
 
 
Results 
53 
 
 
 
Figure 3.21 DSS+MAP treated mice exhibit increased leukocytes in mLN at day 1 after 
secondary challenge. 
Flow cytometry on leukocytes in mLN at day 1 after secondary challenge. Total cell numbers of 
CD19
+
 B cells, CD4
+
 (CD3
+
CD4
+
) and CD8
+
 (CD3
+
CD8
+
) T cells, dendritic cells (CD11b
+
 
CD11c
hi
),PMN (CD11b
+
Ly6G
hi
Ly6C
int
), inflammatory monocytes (CD11b
+
Ly6C
hi
Ly6G
int
) and 
macrophages (CD11b
+
Ly6G
lo
Ly6C
lo
F4/80
hi
) in mesenteric lymph nodes (n=3-5). Graph show a 
representative of at least two independent experiments. *, P<0.05; **, p<0.01; ***,p<0.001, one-
way ANOVA with Tukey’s post test. 
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Figure 3.22 Flow cytometry on leukocytes in colonic lamina propria at day 1 after 
secondary challenge.  
Frequency of CD19
+
 B cells, CD4
+
 (CD3
+
CD4
+
) and CD8
+
 (CD3
+
CD8
+
) T cells, dendritic cells 
(CD11b
+
 CD11c
hi
),PMN (CD11b
+
Ly6G
hi
Ly6C
int
), inflammatory monocytes (CD11b
+
Ly6C
hi
Ly6G
int
) 
and macrophages (CD11b
+
Ly6G
lo
Ly6C
lo
F4/80
hi
) in colonic lamina propria (n=3-5). *, P<0.05; **, 
p<0.01; ***,p<0.001, n.s = not significant, one-way ANOVA with Tukey’s post test. 
 
 
 
Results 
55 
 
Additionally, we observed high frequency of PMN (CD11b+Ly6GhiLy6Cint) in all 
infected groups. Inflammatory monocytes (CD11b+Ly6ChiLy6Gint) were 
increased in all DSS-treated MAP infected groups.  
Next, we investigated the role of adaptive immunity in inducing colitis after 
secondary challenge with MAP. DSS-treated MAP infected RAG2-/- mice were 
challenged with MAP ip and sacrificed at day 1 after secondary challenge. 
Interestingly, we could not observe any reduction of colon length in those mice 
(Figure 3.23A) indicating that cells of the adaptive immune system are 
responsible. 
To assess the key player in this phenomenon, CD4+T cells or CD8+T cells from 
C57BL/6 WT mice were depleted using anti-CD4 or CD8 antibodies two days 
before secondary challenge (Figure 3.23B). Strikingly, reduction of colon length 
was not observed in depleted CD4+ T cells mice (Figure 3.23C). Conversely, 
CD8+ T cells depleted mice still showed a reduction of colon length. Additionally, 
there is no colon length reduction in DSS+MAP+PBS, DSS+PBS+MAP, 
H2O+MAP+PBS and H2O+PBS+MAP (Figure 3.23C). Along the same line, 
colon histology score of depleted CD4+ T cells mice showed significantly lower 
score in comparison to depleted CD8+ T cells and WT mice (Figure 3.23D). 
Moderate infiltration of inflammatory cells and mild epithelial hyperplasia could 
be observed from DSS+MAP+MAP WT and CD8+ T cells depleted mice, 
whereas tissues from DSS+MAP+MAP  CD4+ T cells depleted mice, 
DSS+PBS+PBS, DSS+PBS+MAP and DSS+MAP+PBS showed only low 
infiltration of inflammatory cells (Figure 3.24).  
 
3.13 MAP specific pathogenicity after secondary challenge 
To investigate MAP specific tropism in comparison to other mycobacteria 
species, we infected DSS-treated mice with closely related mycobacteria 
species M. avium ssp. avium (MAA) or M. avium ssp. hominissuis (MAH). At 5 
week after the first challenge, secondary challenge with the same mycobacteria 
was carried out (Figure 3.25A).  
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Figure 3.23 Role of CD4
+
 T cells in colitis.  
A. Upon the autopsy at one day after secondary challenge, colon length of RAG
-/-
 mice was 
measured. Colon lengths in cm (n=4-6). B. Experimental scheme for CD4 and CD8 T cells 
depletion. H2O or 4% DSS were administered to the drinking water from day 1 until day 5, 
followed by normal drinking water afterwards. PBS or 10
8 
CFU MAP in 200 µL i.p. was 
administered two days after DSS treatment finished (day 0). IgG isotype, CD4 or CD8 antibody 
were administered two days before secondary challenge. At 5 weeks p.i, PBS or 10
8 
CFU MAP 
in 200 µL was administered i.p.. Mice were sacrificed at day 1 after secondary challengeC. 
Colon length of CD4 or CD8 depleted and IgG Isotype control mice were measured (n=3-4). D. 
Histology score of the colon were analyzed at one day after secondary challenge (n=3-5). Graph 
show a representative of at least two independent experiments. *, P<0.05; **, p<0.01; 
***,p<0.001, one-way ANOVA with Tukey’s post test. 
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Figure 3.24 H&E staining colon tissue section in CD4
+
 or CD8
+
 T cells depleted mice.  
H&E staining of colon tissue sections at day 1 after secondary challenge. Scale bars, 25 µm. 
H2O+PBS+PBS (upper left) showed normal tissue. DSS+PBS+PBS (upper right), 
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H2O+MAP+MAP (middle left) and DSS+MAP+MAP depleted CD4+ T cells (bottom left) showed 
low infiltration of inflammatory cells (black arrow). DSS+MAP+MAP IgG isotype (middle right) 
and DSS+MAP+MAP depleted CD8+ T cells (bottom right) showed moderate invasion of 
inflammatory cells (black arrow) and mild epithelial hyperplasia. 
 
All infected mice showed enlargement of total liver weight in comparison to 
uninfected groups (Figure 3.25B). Interestingly, mice infected with MAA and 
MAH showed larger total spleen weight in comparison to MAP infected group 
(Figure 3.25C). The most important finding is that only DSS-treated MAP 
infected mice showed reduction of colon length after secondary challenge with 
the same mycobacteria, neither in DSS-treated MAA nor in DSS-treated MAH 
after secondary challenge (Figure 3.25D). These results strongly suggested that 
such bacteria exhibit differential pathogenicity which might be due to a 
differential tissue tropism. Colitis could only be induced in DSS-treated MAP 
infected mice after secondary infection. 
 
Figure 3.25 MAP specific tropism after secondary challenge.  
A. Experimental scheme. H2O or 4% DSS were administered to the drinking water from day 1 
until day 5, followed by normal drinking water afterwards. PBS or 10
8 
CFU MAP, MAA or MAH in 
200 µL i.p. was administered two days after DSS treatment finished (day 0). At 5 weeks p.i, PBS 
or 10
8 
CFU MAP, MAA or MAH in 200 µL was administered i.p.. Mice were sacrificed at day 1 
after secondary challenge. B. Total liver weight in Gram. C. Total spleen weight in Gram. D. 
Colon length of MAP, MAA and MAH infected group at day 1 after secondary challenge with the 
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same mycobacteria species (n=3-5). Graph show a representative of at least two independent 
experiments. *, P<0.05; **, p<0.01; ***,p<0.001, n.s = not significant, one-way ANOVA with 
Tukey’s post test. 
 
3.14 The importance of TLR2 in DSS+MAP mice after 
secondary challenge 
TLR2 play important role for immune activation against mycobacterial infection. 
To investigate the role of TLR2 in present experimental set-up, DSS-treated 
MAP infected TLR2-/- mice were challenged with MAP i.p at 5 week after first 
infection and sacrificed at day 1 after secondary challenge. Significantly larger 
livers were found in H2O+MAP+MAP and DSS+MAP+MAP in TLR2
-/- mice at 
day 1 after secondary challenge (Figure 3.26A). Along the same line, 
enlargement of spleen was observed in H2O+MAP+MAP and DSS+MAP+MAP 
in TLR2-/- mice at day 1 after secondary challenge (Figure 3.26B). Interestingly, 
there was no reduction of colon length in TLR2-/- mice while it could be observed 
in WT DSS+MAP+MAP group (Figure 3.26C). 
Taken together, CD4+ T cells are the important key player in causing colitis in 
DSS-treated MAP infected mice after secondary challenge. The mechanism 
might be via TLR2 signaling which is known as the important factor in immune 
response against mycobacterial infection. Colitis phenomena after secondary 
challenge show the specific tropism of MAP that could not be seen in other 
closely related mycobacteria species.  
 
 
 
 
 
 
Results 
60 
 
 
Figure 3.26 The importance of TLR2 for inducing colitis in DSS-treated MAP infected 
mice after secondary challenge.  
(A-C) Upon the autopsy at one day after secondary challenge of TLR2
-/-
 mice, colon length, liver 
and spleen weight were measured. A. Total liver weight in Gram. B. Total spleen weight in 
Gram. C. Colon length of TLR2
-/-
 mice at day 1 after secondary challenge (n=3-5). Graph show 
a representative of at least two independent experiments. *, P<0.05; **, p<0.01; ***,p<0.001, n.s 
= not significant, one-way ANOVA with Tukey’s post test. 
 
Table 3.1 Cytokines and chemokines multiplex assay at 2h and 24h p.i 
Note: OOR = out of range 
 H20 
+ 
PBS 
2h 
DSS 
+ 
PBS 
2h 
H20 
+ 
MAP 
2h 
DSS 
+ 
MAP 
 2h 
H20 
+ 
PBS 
 24h 
DSS 
+ 
PBS 
 24h 
H20 
+ 
MAP 
 24h 
DSS 
+ 
MAP 
24h 
IL-1α 13,36 18,96 38,3 20,11 22,75 17,3 36,17 53,13 
IL-1β 27,28 130,37 142,71 142,71 45,50 117,68 130,37 380,71 
IL-2 5,60 9,85 8,76 10,91 7,07 11,95 12,46 31,7 
IL-3 OOR < OOR < 0,37 0,12 OOR < 0,58 OOR < 1,87 
IL-4 OOR < 0,52 2,38 1,48 OOR < 1,10 0,52 3,42 
IL-5 14,55 9,46 125,56 14,55 9,46 10,79 15,73 30,46 
IL-6 8,79 32,95 1252,32 873,86 7,73 9,52 67,28 86,68 
IL-9 1,39 31,93 74,59 74,59 22,62 22,62 40,89 147,89 
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H20 
+ 
PBS 
0h 
DSS 
+ 
PBS 
0h 
H20 
+ 
MAP 
0h 
DSS 
+ 
MAP 
 0h 
H20 
+ 
PBS 
 6h 
DSS 
+ 
PBS 
 6h 
H20 
+ 
MAP 
 6h 
DSS 
+ 
MAP 
6h 
IL-10 17,49 20,07 501,99 92,25 18,78 22,65 20,07 88,27 
IL-12 
(p40) 156,73 60,3 395,91 178,53 87,12 40,29 37,56 55,37 
IL-12 
(p70) 23,37 22,4 52,4 40,92 16,27 28,81 24,01 81,64 
IL-13 35,66 47,9 93,22 84,94 23,49 43,82 76,68 185,11 
IL-17 70,93 34,16 36,28 44,42 39,14 32,91 45,89 106,84 
Eotaxin 112,92 54,92 307,72 181,24 54,92 45,98 120,78 266,63 
G-CSF 112,65 3760,78 1536,84 4551,74 62,07 2521,65 26360,02 20367,3 
GM-CSF 11,87 OOR < 72,44 75 OOR < 55,56 61,53 127,23 
IFN-g 1,83 1,90 4,45 3,57 3,5 3,5 2,46 7,93 
KC 132,02 289,8 2753,54 3252,66 23,51 222,38 790,71 726,32 
MCP-1 73,69 123,9 2037,3 1614,44 71,67 114,49 189,47 227,26 
MIP-1a 5,09 7,75 124,94 46,94 5,75 6,15 98,9 131,35 
MIP-1b 10 16,84 239,37 105,27 10 21,89 16,84 43,41 
RANTES 27,1 8,67 31,61 15,38 23,47 8,34 26,43 8,76 
TNF-α 1128,09 849,65 5586,55 1238,83 1017,01 1238,83 849,65 2872,55 
 
Table 3.2 Cytokines and chemokines multiplex assay at 0 and 6h after 
secondary challenge. 
 
H20 
+ 
PBS+PBS 
DSS 
+ 
PBS+PBS 
H20 
+ 
MAP 
+MAP 
2h 
DSS 
+ 
MAP 
+MAP 
 2h 
H20 
+ 
MAP 
+MAP 
 24h 
DSS 
+ 
MAP 
+MAP 
 24h 
IL-1α 14,7 6,1 1,16 10,49 72,11 73,58 
IL-1β 27,28 27,28 90,99 45,50 667,15 457,52 
IL-2 4,67 4,67 6,49 11,43 8284,91 9110,05 
IL-3 OOR < OOR < OOR < OOR < 3,16 3,02 
IL-4 0,08 0,08 0,91 OOR < 3,93 4,10 
IL-5 38,84 18,59 12,71 9,46 496,5 259,48 
IL-6 2,48 2,34 2,91 3,48 8948,15 OOR > 
IL-9 22,62 OOR < OOR < 17,77 129,2 169,9 
IL-10 17,49 8,53 6 12,36 350,41 449,54 
IL-12(p40) 77,24 55,17 189,15 219,78 841,72 1169,19 
IL-12(p70) 20,47 13,34 14,32 17,24 69,38 83,26 
IL-13 15,43 7,44 27,53 60,21 235,72 218,82 
IL-17 34,66 24,8 19,22 26,59 336,4 180,62 
Eotaxin 112,92 45,98 OOR < 36,76 2245,66 5007,7 
G-CSF 148,21 208,14 49,56 970,22 16694,29 28297,56 
GM-CSF 11,87 OOR < OOR < OOR < 112,3 129,9 
IFN-g 2,32 0,45 2,74 2,74 1505,6 2467,31 
KC 24,72 10,02 20,73 50,78 8048,34 7671,89 
MCP-1 75,69 65,42 166,46 117,67 10854 11987,42 
MIP-1a 2,22 0,94 4,70 9,09 215,64 227,95 
MIP-1b 12,83 8,52 9,27 13,51 274,63 518,22 
RANTES 14,73 11,8 41,95 39,53 391,88 502,89 
TNF-α 793,64 339,9 681,24 961,33 5005,62 4209,94 
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4 Discussion 
DSS-induced colitis is a commonly used murine model to study inflammatory 
bowel disease of humans. Symptoms such as diarrhea, bloody feces, mucosal 
ulceration, shortening of colon length and weight loss occur both in DSS treated 
mice and humans suffering from IBD (Wirtz et al., 2007). The chemical DSS 
exerts a direct cytotoxic effect on enterocytes and the protective mucus layer 
resulting in barrier damage and translocation of commensal bacteria associated 
with an inflammatory response (Johansson et al., 2013; Saleh and Elson, 2011). 
For the induction of DSS colitis, the adaptive immune system does not play an 
essential role. In contrast, the innate immune system i.e. TLR and the 
inflammasome are required for tissue repair and protection from colitis (Saleh 
and Elson, 2011). In addition, intestinal mononuclear phagocytes such as 
macrophages and dendritic cells (Qualls et al., 2006) showed a suppressive 
influence on DSS-induced colitis thus supporting the critical role of the innate 
immune system in this model. Even though the adaptive immunity does not play 
an essential role in this model, both T helper (Th)1 and Th2 cells have been 
shown the influence at the later phases to the disease (Dieleman et al., 1998). 
DSS-induced colitis therefore appeared to be a suitable system to test the 
hypothesis that MAP infection is exacerbating an existing colitis. Indeed, MAP 
infection led to a more pronounced reduction in body weight and delayed 
recovery from DSS-induced mucosal damage.  
The reduction of body weight after MAP administration might be due to the 
increased levels of cytokines, such as TNF-α in serum. These increased 
cytokine levels were expected since MAP contains several PAMPs that are able 
to elicit strong innate immune stimulation. However, under inflammatory 
condition by DSS administration, kinetics of cytokines production was altered 
with TNF-α as one of the most obvious and probably one of the most deleterious 
examples. 
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Exacerbation of DSS inflammation by MAP could also be confirmed by the 
analysis of individual organs. The spleen weight was significantly enhanced in 
DSS+MAP mice although the bacterial burden was comparable with the 
H2O+MAP control group. Spleen enlargement was most likely due to an 
increased influx, activation or even expansion of myeloid cells. Similarly, the 
liver was enlarged in DSS+MAP animals in the absence of an increased 
bacterial count. Granuloma formation was observed in both DSS and non DSS 
treated MAP infected animals. However, the granuloma in liver of DSS+MAP 
animals were more frequent and larger as compared to the granuloma found in 
mice only infected with MAP. Again, increased numbers of myeloid cells were 
detected. Granuloma formation contributes to restrict tissue spread of 
mycobacteria. On the other hand, intracellular infection of macrophages within 
granulomas supports mycobacterial survival and persistence in the host 
(Saunders and Britton, 2007). Cytokines and immune cells, particularly T cells 
are required for the formation of such structures (Cooper et al., 1993; Saunders 
et al., 2002). Since DSS treatment not only allows microbial translocation 
through the damaged barrier but also activates immune cells, it might also 
support the formation of larger granuloma in liver.  
Mice treated with DSS and infected with MAP produced stronger antibody 
reactions. Increased total serum IgG was observed and also MAP specific IgG 
showed significantly higher levels. Interestingly, a specific IgG response against 
MAP was also observed in children and adults with Crohn’s disease (Verdier et 
al., 2013). Conversely, in ruminants antibodies against MAP are rarely 
detectable before clinically overt disease (Stabel, 1998). This might be due to 
immune evasion mechanisms of the bacteria which might differentially regulated 
in different species. Future investigations will have to follow the antibody titers in 
more detail over an extended time after infection, since three weeks might be 
too early for the evasion mechanisms to be effective in a chronic MAP infection.  
A recent review suggested that large numbers of MAP might be found in the 
mesenteric tissue of Crohn’s disease patients. MAP might infect endothelial 
cells and proliferate within them. This might cause focal obstruction within 
vessels leading to neo-angiogenesis and ‘creeping fat’ of mesenteric tissue as 
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observed in individuals with CD and JD (Pierce, 2009). Our study confirmed the 
presence of large numbers of MAP in the mesenteric tissue associated with 
granuloma formation and tissue destruction as well as thickening of mesentery. 
However, a more detailed analysis revealed that MAP resided predominantly in 
tissue macrophages in contrast to the postulated residence in endothelial cells 
(Pierce, 2009).  
As discussed above, DSS treatment and MAP infection acts as ‘double hit’. This 
could exacerbate the disease since the immune system is confronted with two 
problems. However, we found that macrophages and both CD4+ and CD8+ T 
cells in the mLN of DSS+MAP treated mice were reduced compared to 
DSS+PBS treated animals. This might be due to cell death induced by the 
presence of MAP in mesentery or other means of bacterial immune evasion (Zur 
Lage et al., 2003).  
A very important finding of this study was that animals of the DSS+MAP group 
showed an enhanced colonization of the colon by MAP. The bacteria might be 
attracted directly by signals of the damaged cells or by the inflammation. Most 
likely, MAP may use myeloid cells like monocytes/macrophages as Trojan 
horses to reach the inflamed tissue. This would also explain why the colon as 
primary target organ of DSS-induced tissue damage is most heavily colonized 
by MAP.  
The mucosal damage itself may help MAP to better survive and persist within 
colonic tissue. The presence of MAP or MAP infected macrophages in the colon 
on the other hand might impair the healing process and thus explain the 
observed delay in tissue recovery. Alternatively, MAP could directly induce 
tissue destruction and delay mucosal tissue recovery. This is supported by the 
high expression of IFN-γ an important cytokine of the anti-mycobacterial host 
defense. Apparently, the presence of higher bacterial counts increased the IFN-
γ expression. On the other hand, high expression of the anti-inflammatory 
cytokine IL-10 might be needed to ameliorate and protect from excessive tissue 
damage due to an overshooting immune response (Couper et al., 2008). 
Interestingly, one study showed complete removal of IL-10 leads to uncontrolled 
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inflammatory responses and disease progression in Mycobacterium tuberculosis 
infection (Higgins et al., 2009). 
The different body weight pattern after first and secondary challenge might be 
due to the altered immune response after a secondary infection. A specific 
memory immune response is expected to elicit a stronger response. The 
reduction of body weight after secondary challenge with MAP might be due to 
the increased levels of cytokines and/or chemokines. Since TLR2 was also 
shown to be involved most likely the stronger response is elicited by a cross talk 
between the innate and the specific immune system. The innate immune 
activation activates a specific adaptive immune response that generates 
cytokines and chemokines storm. 
Strikingly, clinical symptoms of CD and JD became apparent in our mouse MAP 
infection model. Diarrhea as well as a reduction colon length were observed 
after secondary challenge. A reduction of fluid absorption in colon was observed 
as well after secondary challenge with MAP. From previous studies, it was 
known that administration of anti-CD3 antibody leads to high fluid secretion or 
diarrhea. In this model, anti-CD3 injection causes systemic cytokine release and 
acute TNF-dependent diarrhea (Clayburgh et al., 2005; Musch et al., 2002). 
Hence, we hypothesized that after secondary challenge with MAP, adaptive 
immunity, T cells in particular, causes cytokines release which leads to 
reduction of fluid absorption or diarrhea. Nevertheless, there is no difference in 
both DSS-treated or untreated MAP infected after secondary challenge, neither 
from fluid absorption, nor TNF-α and IFN-γ level in serum and colon supernatant 
cytokines production. This might be because DSS-treated MAP infected colon is 
more sensitive to any trigger which leads to colitis after secondary challenge, 
whereas it is not the case in untreated MAP infected colon. 
DSS treatment and MAP infection could exacerbate the disease since the 
immune system deal with two problems. Flow cytometry based analysis results 
from mesenteric lymph nodes showed increasing total number of leukocytes in 
DSS+MAP+MAP and DSS+MAP+PBS. This result suggested there is 
continuously immune activation and proliferation in the draining lymph nodes 
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due to chronic MAP infection and inflammation in the intestine. The phenotype 
supports the hypothesis that MAP could exacerbate the existing colitis. 
A very important finding in this study was the observation of reduction of colon 
length only in DSS-treated MAP infected group after secondary challenge. CD4+ 
T cell are the key players for this phenomenon. In mycobacteria infection, CD4+ 
T cells were shown to have an important role in antibacterial protection (Ehlers 
and Schaible, 2012). The presence of CD4+ T cells accelerates granulomatous 
response because of it enhances the production of TNF-α and IFN-γ at the site 
of infection (Hänsch et al., 1996). On the other hand, CD4+ T cells also 
important in inducing colitis. Clonal T cell populations that are highly specific for 
intestinal bacterial antigen can induce colitis (Kullberg et al., 2003). CD4+ T cell 
with high expression of CD45RB could induce a pathogenic Th1 response that 
leads to colitis (Powrie et al., 1994). Based on those finding, it was speculated 
that after secondary infection, MAP specific CD4+T cells were activated and 
proliferated. This leads to production of effector T cells which then induce colitis.  
Additionally, the increasing frequency of PMN in all groups that were infected at 
5 week time point showed the recruitment of PMN during the acute phase of 
MAP infection. In contrast, increasing frequency of colonic inflammatory 
monocytes in all DSS-treated MAP infected groups showed that there is more 
immune activation. Recruitment of inflammatory monocytes is essential for 
controlling and clearance bacterial infection (Shi and Pamer, 2011). Under these 
conditions, the host is not only facing MAP but also bacterial translocation from 
intestine.  
MAP showed different pathogenicity compared to the closely related 
mycobacteria species, such as MAA and MAH. Although both species showed 
higher immune activation from total liver and spleen weight, only MAP showed 
reduction of colon length after secondary challenge. This might be because only 
MAP has a correlation with JD and also CD which are inflammatory bowel 
disease in animals and human. This might be exerted by a differential tissue 
tropism which however needs to be demonstrated. 
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An interesting finding in the present study is that no reduction of colon length in 
TLR2 deficient mice was observed after secondary challenge. This might be a 
clue for the mechanism of CD4+ T cells reactivation in MAP infection. Previous 
study showed an importance of TLR2 in CD4+ T cells induction or reactivation 
during mycobacteria infection (Heldwein et al., 2003). Based on that, the 
reactivation of CD4+ T cells might need TLR2 signaling to become activated.  
In conclusion, the present study provides evidence that MAP infection might 
exacerbate and prolong an existing inflammatory intestinal disease. Several 
aspects described for JD and CD such as the presence of MAP in macrophages 
of the mesenteric tissue or strong inflammation of the colonic mucosa were also 
observed in present model. Stronger immune responses were observed in MAP 
infection of inflamed tissue after secondary challenge. TLR2 appears to be 
necessary from the reactivation of CD4+ T cells. This activation then leads to 
induction of colitis and diarrhea which are the clinical symptoms of JD and CD. 
Thus, the presented model might facilitate a more in-depth analysis of the 
association of MAP with intestinal mucosal inflammation including the 
underlying molecular mechanisms in the future. 
 
.  
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5 Summary 
In current study, it was hypothesized that MAP might not be the causative agent 
of CD, but exacerbating an already existing disease. Secondly, due to long 
disease progression from sub-clinical phase to the clinical phase and ubiquitous 
exposure of animals to environmental MAP, it was further hypothesized that 
infected animals will reveal the clinical symptoms after secondary exposure to 
MAP. This might be also the case in CD. Based on both hypotheses, dextran 
sulfate sodium-induced colitis was combined with MAP infection.  
The exacerbation due to the infection was evident from the increasing liver and 
spleen weight after infection in DSS-treated MAP infected mice. In addition, 
higher number and larger liver granuloma were observed in that group. 
Furthermore, higher numbers of viable bacteria were found in the colon of 
DSS+MAP mice in comparison to untreated MAP infected mice. Interestingly, 
the tissue recovery was delayed in DSS+MAP in comparison to DSS-treated 
uninfected mice. Additionally, large numbers of MAP were found in mesentery 
that caused large granuloma and necrotic regions. Thus, according to the 
original hypothesis MAP infection indeed exacerbates the existing inflammation. 
Upon secondary infection, DSS-treated MAP infected mice came down with 
diarrhea. Colitis was also observed. Both of which are also the clinical 
symptoms of JD and CD. An increased frequency of CD4+ T cell in the colon 
and the prevention of colitis by depletion of CD4+ T cells demonstrate the 
importance of CD4+ T cells in the pathogenesis of MAP infection after 
secondary challenge. Interestingly, specific activity of MAP was found when 
other mycobacteria were compared and failed to induce similar effects. This 
might be due to a specific tissue tropism of MAP. Furthermore, reduction of 
colon length could not be observed in TLR2 deficient mice suggesting an 
involvement of innate receptors during reactivation of potentially MAP specific 
CD4+ T cells.  
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Taken together, these results are consistent with the previous hypothesis that 
MAP exacerbates the existing colitis. Thus, the mouse model presented here 
reflects histopathological aspects of JD and might in the long run help to 
understand a possible association between MAP and CD in humans.  
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6 Appendix 
6.1 Abbreviation 
 
μg: microgram  
 
μl: microliter 
 
oC: degree Celcius   
 
AIDS: Acquired Immune Deficiency 
Syndrome 
 
APC: antigen presenting cells 
 
APC: allophycocyanin  
 
ATG16L: Autophagy-related protein 
16-1 
 
BCG: Bacillus Calmette-Guérin  
 
bp: basepairs  
 
BSA: bovine serum albumin 
 
C: cytosine 
 
CARD:  caspase-activating 
recruitment domain 
 
CD: cluster of differentiation  
 
CD: Crohn´s diseases 
 
CFU: colony forming unit 
 
Cm: centimeter 
 
Cy: Cyianine  
 
ddH2O: double distilled water  
DC: dendritic cells 
 
DNA: deoxyribonucleic acid  
 
DSS: Dextran Sulfate Sodium 
 
DTT: dichlorodiphenyltrichloroethane 
 
EDTA: Ethylenediaminetetraacetic acid 
 
ELISA: Enzyme Linked Immunosorbent 
Assay  
 
et al.: and others   
 
FCS: Fetal Calf Serum 
 
FITC: fluorescein isothiocyanate  
 
FoxP3: Forkhead-Box-Protein P3 
 
G: guanine 
 
G-CSF: Gronulocytes-stimulating factor  
 
GM-CSF: colony-stimulating factor 
 
GWAS: genome-wide association 
studies 
 
h.: hours  
 
H&E: hematoxylin and eosin  
 
HEK: Human Embryonic Kidney 
 
HEPES: 4-(2-hydroxyethyl)-1-
piperazineethanesulfonic acid  
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i.p.: intraperitoneal  
 
IBD: inflammatory bowel disease  
 
IFN: interferon 
 
Ig: Immunoglobulin  
 
IL: interleukin  
 
IS: Insertion Element 
 
IMDM: Iscove's Modified Dulbecco's 
Medium 
 
JD: Johne´s disease  
 
KC: Keratinocyte-Derived 
Chemokine 
 
l: liter  
 
LAM: lipoarabinomannan 
 
LM: Lipomannan 
 
LPS: Lipopolysaccharide 
 
Ly6: lymphocytes antigen 6 complex 
 
M: molar  
 
MAA: Mycobacterium avium ssp. 
avium  
 
MAC: Mycobacterium avium 
complex 
 
MAH : Mycobacterium avium ssp. 
hominissuis  
 
MAP: Mycobacterium avium ssp. 
paratuberculosis  
 
MCP-1: monocyte chemoattractant 
protein-1 
 
mg: milligram  
 
MHC-I: major histocompatibility complex 
class one 
 
MHC-II: major histocompatibility complex 
class two 
 
MIP: macrophage inflammatory protein 
 
ml: milliliter  
 
mLN: mesenteric lymph nodes  
 
mm: millimeter  
 
mM: millimolar 
 
MPO: myeloperoxidase  
 
MTB: Mycobacterium tuberculosis  
 
NOD: nucleotide oligomerization domain  
 
NK: Natural killer 
 
n.d: not detectable 
 
n.s: not significant 
 
PAMPs: Pathogen-associated molecular 
patterns 
 
PBMC: peripheral blood mononuclear 
cells 
 
PBS: Phosphate buffered saline 
 
PCR: polymerase chain reaction 
 
PE: Phycoerythrin 
 
PerCP: peridinin chlorophyll protein 
 
p.i: post infection 
 
PMN: Polymorphonuclear 
 
RAG: recombination activating gene  
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RANTES: Regulated on Activation 
Normal T Cell Expressed and 
Secreted 
 
RPMI: Roswell Park Memorial 
Institute 
 
RNA: Ribonucleic Acid 
 
STAT3: Signal Transducer and 
Activator of Transcription 3 
 
 
 
TGFβ: Transforming Growth Factor-β 
 
TLR: Toll-like receptor 
 
TNF: Tumor Necrosis Factor 
 
w.k: week 
 
ZN: Ziehl Neelsen  
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